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ABSTRACT 
 
The work in this dissertation links two diseases through a protein secreted by 
Dictyostelium discoideum cells. The protein, AprA, inhibits cell proliferation and 
induces chemorepulsion (movement away) of Dictyostelium cells. This has implications 
in both cancer research and the study of Acute Respiratory Distress Syndrome.  
Cancer is a misregulation of cellular proliferation. Often the removal of a 
primary tumor results in rapid metastatic cell proliferation. The rapid proliferation of 
metastatic cells indicates the presence of a factor, called a chalone, secreted by the 
primary tumor cells, that inhibits metastatic cell proliferation. The ability of AprA to 
inhibit proliferation of the cells that secretes it classifies it as a chalone. Using the model 
organism Dictyostelium and the protein AprA allows us to study chalone signaling 
mechanisms.  
Acute Respiratory Distress Syndrome (ARDS) is characterized by an excess 
influx of neutrophils into the lungs. Neutrophils damage the lung tissue and ultimately 
recruit more neutrophils that repeat the process. A need exists to remove these cells and 
allow resolution to occur. One way to accomplish this is through chemorepulsion, the 
directional movement of cells away from an external cue. We can use AprA to study the 
mechanisms of chemorepulsion.  
In this dissertation, I have found that the PTEN-like protein CnrN, which is an 
inhibitor of proliferation and chemotaxis, is involved in both AprA proliferation 
inhibition and chemorepulsion of Dictyostelium cells. I have shown that the human 
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protein DPPIV, which is structurally similar to AprA, causes chemorepulsion of human 
neutrophils. Additionally, aspirated DPPIV reduces the accumulation of neutrophils in 
the lungs of a mouse model of ARDS. Work shown in the appendices suggests that 
AprA signals through specific G protein-coupled receptors.   
The work in this dissertation studies the role of chalones and chemorepellents. It 
allows the unique opportunity to study chemorepulsion in both Dictyostelium and human 
cells. The hope and goal is that the work in this dissertation could lead to novel therapies 
for diseases such as cancer and ARDS.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Chalones 
 The ability of tissues or a group of cells to regulate their number of cells can be 
explained simply by the chalone theory. A chalone is a factor, secreted by cells, that acts 
by inhibiting cell division (1, 2). Historically, chalones referred to small oligopeptides, 
purified from homogenates, that inhibited cellular division of a specific tissue (2). These 
factors included chalones for tissues such as bone marrow, liver, epidermis, and thymus, 
but researchers were unable to verify these factors were actually secreted  (2-7). The 
discovery of factors other than oligopeptides, such as the protein myostatin, revived the 
chalone theory (8).  
The most well characterized chalone is myostatin, which regulates the amount of 
muscle an organism has (9). Myostatin belongs to the TGF-β superfamily, which is 
thought to contain several chalones, including an olfactory epithelium chalone (10). 
Significant increases in muscle mass are observed in myostatin knockout mice and cattle 
with mutations of the myostatin gene (11, 12). Overexpression of myostatin in mice 
causes a dramatic loss of muscle mass and wasting (13). Myostatin acts by inhibiting the 
proliferation of myoblasts, the muscle cells precursors, mediated through various 
downstream signals, some of which have been identified (14-17).  
Although we know how myostatin functions to inhibit myoblast proliferation, 
much less is known about the chalones and their mechanisms within the larger field of 
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chalones. The theory suggests that as a tissue size increases, the concentration of chalone 
will increase to stop or slow proliferation until a tissue or group of cells reaches its ideal 
size (10). The evidence for factors that regulate cell division is widespread. Unlike the 
case for myostatin, for many tissues the chalone and associated signal transduction 
pathways are unknown. For example, the melanocyte chalone can be injected into the 
skin, under a melanoma and the chalone will inhibit further proliferation of the 
melanoma through unknown mechanisms (18, 19). An unknown liver chalone regulates 
the division of cells in damaged livers to regrow the liver to its original size (20, 21). A 
splenectomized mouse regrows implanted pieces of spleen to the exact mass of its 
removed spleen (22). One of the most intriguing examples of the existence of chalones is 
observed in cancer patients who have their primary tumors removed. In these patients, 
metastases begin to proliferate rapidly after the primary tumor is removed (23-28). All of 
these examples point toward the existence of factors, such as chalones, that sense cell 
density and can regulate cell proliferation.  
 
Dictyostelium discoideum 
 Dictyostelium discoideum diverged on the evolutionary tree following plants but 
prior to fungi (29). Despite its early divergence, Dictyostelium shares more homologous 
genes with mammals than yeast does with mammals (29-31). In 2005, the entire 34 Mb 
Dictyostelium discoideum haploid genome was sequenced and recently genome-wide 
RNA-seq was completed (32, 33). Both of these, along with gene annotations, are 
provided on a NIH-funded, open-access webpage http://dictybase.org/. Additionally, the 
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site offers strains, transformants, and vectors through an NIH-funded stock center. A 
number of features make Dictyostelium an ideal eukaryotic model. Axenic strains (Ax) 
can grow in simple media with a doubling time of approximately twelve hours, making 
Dictyostelium inexpensive and easy to maintain in the laboratory. Dictyostelium cells 
can also be grown on agar plates, where they chemotax toward and ingest bacteria. Cells 
can be manipulated easily; mutagenesis can be done through restriction enzyme-
mediated insertion or shotgun antisense and vectors can be expressed through simple 
transfection (34-37). In addition to its vegetative growth in the presence of nutrients, 
Dictyostelium cells can undergo development. When starved, Dictyostelium cells 
chemotax toward relayed pulses of cAMP and form fruiting bodies which each contain 
approximately 20,000 cells. These attributes make Dictyostelium a good model to study 
tissue size regulation, chemotaxis, and signal transduction (38).  
 
Dictyostelium Chalones  
 Dictyostelium produces two chalones, AprA and CfaD (39, 40). AprA and CfaD 
act as inhibitors of vegetative Dictyostelium proliferation (39, 40). Cells lacking either 
AprA or CfaD proliferate faster than wild type cells (39, 40). Mutant fast proliferation 
phenotypes can be rescued by expressing AprA or CfaD in their respective mutant 
backgrounds (39, 40). In agreement with the chalone theory, the concentrations of AprA 
and CfaD increase as the Dictyostelium cell density increases (40, 41). The translation of 
AprA and CfaD proteins is regulated by eIF2α phosphorylation (42). When recombinant 
AprA (rAprA) or recombinant CfaD (rCfaD) are added to wild type cells, they slow the 
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proliferation of wild type cells (40, 41). rAprA rescues the aprA¯ phenotype, but not 
cfaD¯ phenotype, and rCfaD rescues the cfaD¯ phenotype but not aprA¯ (40, 41). Both 
proteins are therefore necessary for the inhibition of proliferation. Although AprA and 
CfaD are both necessary, they appear to activate separate G protein-coupled receptors 
(unpublished data) and downstream signaling molecules (43). This is in agreement with 
the observation in other systems that some chalones may function through G protein-
coupled receptors (2, 44). AprA signals through the Gα protein Gα8 and an unidentified 
G protein-coupled receptor, while CfaD appears to function through Gα1 and an 
unknown G protein-coupled receptor (43). Several downstream signaling components of 
AprA and CfaD have been identified including BzpN, a leucine zipper transcription 
factor, and QkgA, a tyrosine kinase-like ROCO kinase, and RblA, the tumor suppressor 
retinoblastoma (45-47).  
 Apart from its role as a chalone, AprA functions as a chemorepellent of 
Dictyostelium cells (48). When wild type Dictyostelium cells are plated on agar, cells 
tend to move outward away from the dense colony center (46). Cells lacking AprA 
maintain a tight colony edge and do not move outward from the colony (46). Cells move 
in a biased direction away from a source of rAprA, but not in a biased direction from 
buffer alone or buffer containing the chalone rCfaD (48). While AprA affects the 
direction of cell movement, AprA does not affect the speed at which the cells move (48). 
The chemorepellent activity of AprA is dependent on CfaD, the ROCO kinase QkgA, 
and the Gα protein Gα8 (48). AprA does not require BzpN, phospholipase C (PLC), or 
the Dictyostelium phosphatidylinositol 3-kinase (PI3K) 1 or 2 to induce chemorepulsion 
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(48). Similar to Dictyostelium cell movement outward from a colony, some researchers 
have suggested that chemorepellents exist within tumors to cause these cells to move 
away from the cell-dense tumor and promote invasion and metastases (49).  
 
Chemotaxis 
 The directed movement of cells, or chemotaxis, can occur when a cell senses a 
gradient of an external cue. Eukaryotic cell chemotaxis has been most extensively 
studied in Dictyostelium and its mammalian counterpart, the neutrophil (38, 50-52). Both 
types of cells can bias their directional movement based on external cues. Dictyostelium 
offers the advantage of genetic manipulation, which is difficult in the short-lived 
neutrophil. Chemoattraction, the movement of cells toward an external cue, is well 
studied in both models. Dictyostelium cells migrate toward the bacterial product folate in 
their vegetative state and cAMP during development (53). Neutrophils migrate toward a 
number of chemoattractants including the bacterial product f-Met-Leu-Phe (fMLP) and 
interleukin-8 (IL-8) secreted by macrophages and epithelial cells (54, 55).  
 The signal transduction pathways mediating Dictyostelium and neutrophil 
chemotaxis are highly conserved (51, 56). Chemotaxis begins with the ability to sense a 
gradient of chemoattractant. Typically, chemoattractants are sensed by detecting higher 
concentrations of the chemoattractant on one side of the cell through uniformly 
expressed G protein-coupled receptors (51, 57). Directional movement is dependent on 
the maintenance of cell polarity and the formation of pseudopods to move the cell 
forward (50, 51). When a cell polarizes, the cell becomes elongated and alters the 
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localization of protein signals within the cell body (51). G protein-coupled receptors 
signal to PI3K which phosphorylates the membrane lipid phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and increases PIP3 
at the leading edge (end of the cell closest to the attractant) of the cell where it promotes 
pseudopod formation to move the cell forward (38, 51, 58-60). Sites of actin filament 
rearrangement are induced by PIP3 and these sites are locations of pseudopod formation 
(61). At the rear of the cell, phosphatase and tensin homolog (PTEN) prevents the 
buildup of PIP3 by dephosphorylating PIP3 back into PIP2 (38, 51, 58, 62). In this way, 
PTEN inhibits the formation of pseudopods in the opposite direction of the 
chemoattractant signal (38, 51, 58, 62). An effector of PI3K signaling and a small 
GTPase, Rac, helps regulate pseudopod formation at the leading edge through actin 
polymerization (51). Additionally, Rac inhibits Rho, another small GTPase at the 
leading edge (51). Consequently, Rho becomes polarized to the trailing edge where it 
interacts with PTEN to promote myosin filament formation and inhibit actin formation, 
thereby inhibiting pseudopod formation (51). By maintaining or altering the polarization 
of these internal signals, cells can manipulate their directional movement toward a 
chemoattractant.  
 Another form of direct cell movement is chemorepulsion, where cells move away 
from a given signal. Although many cell types have the ability to undergo both 
chemoattraction and chemorepulsion, the mechanisms are not as well characterized for 
chemorepulsion as they are for chemoattraction. Many cells have been observed 
chemotaxing toward (chemoattraction) and away from (chemorepulsion) external cues 
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including Dictyostelium cells, neutrophils, mast cells, neuronal cells, and cancerous cells 
(49, 63-66). In the developing brain, neuronal chemorepellents such as semaphorins, 
netrin-1, and Slit help guide axon growth (66-68). Later axon growth is blocked by 
migratory inhibitory cues such as myelin-associated glycoprotein (MAG) (69). Recently, 
MAG was shown to activate PTEN, indicating chemorepellents, at least in neurons, 
might function by potentiating inhibitory signals to induce polarity (69). An analog of 
cAMP causes chemorepulsion in Dictyostelium cells (65). Similar to neurons, these 
repulsed Dictyostelium cells show a reversal of chemoattractive signaling, where PTEN 
is localized nearest the cue to prevent movement/pseudopod formation in the direction of 
the repellent (65). At high concentrations, IL-8, usually a chemoattractant of neutrophils, 
becomes a chemorepellent of neutrophils (64). Cells in a gradient of high IL-8 also show 
a reverse of attractant signaling, suggesting neutrophils may also use similar pathways in 
chemoattraction and chemorepulsion (64). Akt, an effector of PI3K, is localized to the 
leading edge of the cells (the edge away from the highest concentration of IL-8) (64). 
During inflammation, neutrophils move from the bloodstream into a damaged/infected 
tissue (70). Most neutrophils are thought to undergo apoptosis within the tissue as 
resolution begins (70). Reverse migration, or movement of neutrophils back into the 
bloodstream, can be observed in the wounds of zebrafish (71). A number of groups have 
shown that mammalian neutrophils can undergo reverse migration identified by altered 
expression of proteins on the neutrophils (72, 73). Reverse migration may be caused by 
either chemoattractant or chemorepellent signals.  
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Dipeptidyl Peptidase IV 
Dipeptidyl peptidase IV (DPPIV) is a protein belonging to a large group of 
“DPPIV activity and/or structure homology” (DASH) proteins (74-79). DPPIV is a 100 
kDa serine protease which cleaves peptides with a proline or alanine in the second 
position at the N-terminus. The active site of DPPIV is a triad including Ser630, Asp708, 
and His740 (77). DPPIV is active as a dimer in the plasma membrane of some 
lymphocytes and epithelial cells and a heavily glycosylated soluble form of DPPIV is 
also found in plasma, serum, cerebrospinal fluid, synovial fluid, semen, and urine (75, 
76, 79-81). The glycosylation has been predicted to be important for the enzymatic 
activity of DPPIV (75, 81).  
The role of DPPIV is extensive. Functions of DPPIV can be broken down into 
two main categories proteolytic and cellular communication (82). In the blood, DPPIV 
cleaves a number of substrates. One of DPPIV’s main substrates is glucagon-like 
peptide-1 (GLP-1), an incretin that regulates insulin levels (83). Incretins are increased 
in response to glucose ingestion (83). Incretins subsequently increase insulin secretion 
and therefore glucose uptake from the blood (83). DPPIV inhibits incretin function 
through enzymatic cleavage (83). Inhibitors of DPPIV are being used as treatment for 
type 2 diabetes where glucose uptake from the blood is misregulated (83). The inhibitors 
allow a longer half-life of the incretins to influence insulin secretion and glucose uptake 
(83). DPPIV also cleaves stromal-derived factor 1 (SDF-1) the ligand for CXCR4 (84). 
SDF-1 is a chemoattractant for CD34+ hematopoietic progenitor cells (HPCs) (85). 
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When cleaved by DPPIV, the affinity of SDF-1 for CXCR4 decreases, allowing HPCs to 
migrate into the bloodstream (85).  
DPPIV binds to many binding partners to elucidate different cellular responses. 
The membrane form of DPPIV binds adenosine deaminase (ADA), which metabolizes 
adenosine (86). DPPIV-ADA binding and ADA accumulation at the cell surface is 
proposed to aid T-cell proliferation that is inhibited by excess adenosine (86). The 
cytoplasmic domain of membrane DPPIV interacts with CD45, a membrane-linked 
tyrosine phosphatase, and initiates signaling to downstream effectors (87). DPPIV also 
interacts with the mannose 6-phosphate receptor, a partnership that results in receptor 
internalization following T-cell activation (87). Interactions between DPPIV and the 
extracellular matrix protein molecules fibronectin and collagen are thought to increase 
cell migration (87). Additionally, soluble DPPIV (sDPPIV) can up-regulate CD86 on 
monocytes through a co-stimulation interaction with caveloin-1 to activate T-cells (75, 
88). 
Mice lacking DPPIV have been generated (89) and rat strains with spontaneous 
mutations of DPPIV have been identified (90, 91). There appears to be no defect in 
blood cell production as DPPIV deficient animals have normal blood levels of most 
leukocytes (92-94). When DPPIV knockout mice have experimentally induced arthritis, 
an increased severity is observed with more than a 2-fold increase in the number of cells 
in the joint (95). DPPIV deficient rats have an increase in neutrophils in ovalbumin-
induced lung inflammation (96). Reduced levels of DPPIV correlate with increased 
inflammation in the joints of rheumatoid arthritis patients (97). The increased 
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inflammation observed in DPPIV deficient situations has been assumed to be due to a 
persistent chemokine presence, as DPPIV was not present to cleave those chemokines 
(98).  
DPPIV has a complex role in disease. Aggressive lymphomas and gliomas are 
associated with increased expression of DPPIV (75, 99), while melanoma progression is 
associated with decreased DPPIV expression (75, 99, 100). The conflicting implications 
of DPPIV in disease are probably due to misregulation of DPPIV substrates from altered 
levels of enzymatic activity. DPPIV’s role in blood/glucose regulation (diabetes), 
activation and inactivation of chemokines (cell migration and immune response), 
neuropeptides, and vascular regulatory peptides (angiogenesis), tissue remolding (wound 
healing), fibroblast activation (immune response, fibrosis), cell adhesion, gives it a wide 
range of processes where its misregulation would prove detrimental or beneficial (77, 
81, 99).   
 
 
Acute Respiratory Distress Syndrome 
 Damage to the lung tissue in Acute Respiratory Distress Syndrome (ARDS) 
ultimately results in respiratory failure followed by death in 40% of patients respiratory 
assistance, such as mechanical ventilation, and 90 % of unassisted patients (101-103). 
ARDS can develop following gas or acid inhalation, sepsis, trauma, pneumonia, or 
severe burns (104-106). In early stages of ARDS, alveolar epithelial cells are damaged 
causing a vascular leak (106). Immune cells, primarily neutrophils, infiltrate the alveolar 
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space (105, 106). Neutrophils release reactive oxygen species and proteases that 
exacerbate the damage to lung tissue (105, 106). Resolution of the damage, edema, and 
removal of neutrophils from the lung tissue may all be misregulated in ARDS (102, 103, 
107). Although approximately 60% of patients recover from ARDS, their overall quality 
of life is reduced and includes chronic respiratory problems, fibrosis, and cognitive 
problems such as depression (104, 108, 109). No treatments to date have been effective 
(103, 105). Cell based therapies are currently being investigated (103). The best 
treatment is management of lung integrity until resolution occurs (103). 
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                                               CHAPTER II                         
A DICTYOSTELIUM SECRETED FACTOR REQUIRES A PTEN-LIKE 
PHOSPHATASE TO SLOW PROLIFERATION AND INDUCE 
CHEMOREPULSION
1
 
 
Summary 
In Dictyostelium discoideum, AprA and CfaD are secreted proteins that inhibit 
cell proliferation. We found that the proliferation of cells lacking CnrN, a phosphatase 
and tensin homolog (PTEN)-like phosphatase, is not inhibited by exogenous AprA and is 
increased by exogenous CfaD. The expression of CnrN in cnrN¯ cells partially rescues 
these altered sensitivities, suggesting that CnrN is necessary for the ability of AprA and 
CfaD to inhibit proliferation. Cells lacking CnrN accumulate normal levels of AprA and 
CfaD. Like cells lacking AprA and CfaD, cnrN¯ cells proliferate faster and reach a 
higher maximum cell density than wild type cells, tend to be multinucleate, accumulate 
normal levels of mass and protein per nucleus, and form less viable spores. When cnrN¯ 
cells expressing myc-tagged CnrN are stimulated with a mixture of rAprA and rCfaD, 
levels of membrane-associated myc-CnrN increase. AprA also causes chemorepulsion of 
Dictyostelium cells, and CnrN is required for this process. Combined, these results 
suggest that CnrN functions in a signal transduction pathway downstream of AprA and 
CfaD mediating some, but not all, of the effects of AprA and CfaD. 
_________________ 
1 Reprinted with permission. Originally published in PLoS ONE. Herlihy SE, Tang Y, Gomer RH. 2013. A 
Dictyostelium secreted factor requires a PTEN-like phosphatase to slow proliferation and induce 
chemorepulsion. PLoS ONE. 8(3).   
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Introduction  
Much remains to be understood about how tissue size is regulated. A possible 
way to regulate tissue growth is through secreted autocrine factors that slow the 
proliferation of cells in that tissue. A variety of observations suggest the presence of 
such factors (often referred to as chalones) in many different tissues, but little is known 
about these factors and their signal transduction pathways (8, 9, 45, 46, 110). Two such 
secreted autocrine factors have been identified in the model organism Dictyostelium 
discoideum. These proteins, AprA and CfaD, inhibit the proliferation of Dictyostelium 
cells as a population becomes dense. Strains lacking AprA or CfaD proliferate rapidly 
(39, 40, 42). Cell proliferation is slowed by adding recombinant AprA (rAprA) or 
recombinant CfaD (rCfaD) to cells, or by overexpressing these proteins (40, 41). Both 
aprA¯ and cfaD¯ cells are multinucleate (39, 40). Although AprA and CfaD affect 
proliferation, cells lacking these proteins show mass and protein accumulation on a per 
nucleus basis similar to that of wild type cells, indicating that AprA and CfaD do not 
affect the growth of cells (39, 40). In addition to inhibiting proliferation, AprA also 
causes chemorepulsion of cells, suggesting that AprA helps to disperse a colony of cells 
(48). When starved, Dictyostelium cells develop to form fruiting bodies containing 
spores that can be dispersed to areas with higher nutrient concentrations. The ability to 
form viable spores is therefore advantageous. Although AprA and CfaD slow 
proliferation and appear to be deleterious, these proteins help spore development and are 
thus advantageous for development (39, 40).   
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 During development, Dictyostelium cells aggregate using relayed pulses of 
cAMP as a chemoattractant. The cells move up a gradient of extracellular cAMP by 
extending pseudopods in the direction of the cAMP source (62, 111, 112). 
Phosphatidylinositol 3-kinase (PI3K), which phosphorylates the membrane lipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate 
(PIP3), translocates from the cytosol to the membrane at the leading edge of the cell in 
response to cAMP and mediates actin polymerization and pseudopod formation (38, 58-
60). PTEN negatively regulates the effect of PI3K by dephosphorylating PIP3 to PIP2 
(38, 62, 113). When PTEN is localized to the membrane of cells, it inhibits the formation 
of pseudopods (38, 58, 62). When PI3K translocates to the leading edge and PTEN 
localizes to the back edge of the cell, pseudopod formation is inhibited at the back of the 
cell, enabling movement toward cAMP (58, 111, 114).   
CnrN is a PTEN-like protein in Dictyostelium that has PTEN-like phosphatase 
activity (115, 116). In the absence of CnrN, levels of PIP3 are higher than in wild-type 
cells (115). Akt, a downstream target in PI3K pathways, usually requires translocation 
and phosphorylation from the cytosol to the membrane for its activation (117-119). 
During development, Akt translocation and phosphorylation is increased in the absence 
of CnrN (115). The increases in Akt translocation, Akt phosphorylation, and levels of 
PIP3 in cnrN¯ cells suggests that CnrN acts as a negative regulator of PIP3 and Akt, 
which are both components of PI3K pathways (115, 119). Like PTEN, CnrN plays a role 
in Dictyostelium development. By antagonizing the PI3K pathway, CnrN negatively 
regulates the production of cAMP and stream breakup during aggregation (115). 
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Compared to wild type cells, cnrN¯ cells have smaller aggregation territories and 
fruiting bodies, increased cell motility, number of aggregation territories, cAMP levels, 
Akt translocation, and actin polymerization, move faster, move further toward cAMP, 
are insensitive to counting factor, and have shorter streams (115). All of these 
phenotypes are rescued by the expression of a myc-tagged CnrN in the cnrN¯ cells 
(cnrN¯/CnrNOE)(115). 
In mammalian cells, PI3K signaling leads to cell proliferation (113, 120, 121). 
PIP3 binds to downstream effectors such as PDK1 and Akt, which play a role in cell 
proliferation, growth, and survival (113, 120, 122-124). As PTEN effectively counteracts 
PI3K, it negatively regulates proliferation in mammalian systems and functions as a 
tumor suppressor (113, 125-128). Here we report that CnrN is necessary for the 
inhibition of proliferation by AprA and CfaD as well as AprA-induced chemorepulsion, 
indicating that CnrN acts as a negative regulator of proliferation in a chalone signal 
transduction pathway and mediates AprA-induced chemorepulsion.  
 
Materials and Methods 
Ax2 wild-type and cnrN¯ clone DBS0302655 (115) were grown in HL5 media 
(Formedium Ltd, Norwich, England) as previously described (129).  cnrN¯/CnrNOE 
clone DBS0302656 and Ax2/CnrNOE clone YT05A cells were cultured in HL5 
containing 15µg/ml geneticin (115).  Recombinant AprA and CfaD were made following 
Bakthavatsalam et al. (40). Levels of extracellular AprA and CfaD were compared by 
starting cultures of cells in axenic shaking culture at 1.25 x 106 cells/ml and collecting 
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cells by centrifugation at 3000 x g for 4 minutes when cultures were at 2 x 106 cells/ml. 
A sample of the conditioned medium supernatant was mixed with an equal volume of 
2X loading buffer and heated to 95°C for 5 minutes. 10 μl of these samples were run on 
4-20% polyacrylamide gels, and Western blots were stained for AprA as previously 
described (39) or for CfaD as previously described (40). DAPI staining of nuclei was 
done as described (39). Proliferation inhibition, spore viability, mass and protein 
determination, doubling time calculations, and statistics were done as previously 
described (46) with the exception that for spore viability assays, 107 cells were washed 
twice in 8 ml PDF (20 mM KCl, 9.2 mM K2HPO4, 13.2 mM KH2PO4, 1 mM CaCl2, 2.5 
mM MgSO4, pH 6.4) prior to resuspension. In addition, proliferation inhibition was 
measured using a combination of rAprA and rCfaD, both at 300 ng/ml. Fluorescence 
microscopy was conducted following (130, 131). Briefly, vegetative cells were placed in 
8-well chambered glass slides (Nalge Nunc 177402) at a density of 5 x 104 cells/well, 
fixed with 3.7% formaldehyde for 10 minutes, and permeabilized with 0.5% TritonX-
100 in PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) 
for 5 minutes. Cells were stained with a 30-minute incubation with anti-Myc antibodies 
(Bethyl Laboratories) and a subsequent 30-minute incubation with Alexa Fluor 488 
conjugated anti-rabbit IgG (Invitrogen) in PBS containing 0.05% NP-40 and 0.5% BSA 
at room temperature. Images were taken using an Axioplan Fluorescence Microscope 
(Carl Zeiss). Binding of AprA, CfaD, a mixture of both, or an equal volume of buffer to 
myc-tagged cnrN¯/CnrNOE cells was done as previously described (41, 43). Membranes 
were collected as previously described (41, 43), and Western blots of membrane samples 
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were stained with anti-Myc antibodies. Membranes were re-probed with anti-AprA and 
anti-CfaD antibodies (Bethyl Laboratories). Chemorepulsion assays were done as 
previously described (48). 
 
Results 
cnrN¯ cells show aberrant proliferation inhibition by AprA and CfaD 
The proliferation of wild-type cells is inhibited by AprA or CfaD (39-41). If 
AprA and/or CfaD transduce signaling through CnrN, we would expect cnrN¯ cells to be 
insensitive to AprA and/or CfaD. We incubated proliferating cells with rAprA or rCfaD 
and determined the decrease in cell density compared to a buffer control after a 16-hour 
incubation. As previously observed, wild-type cells had an approximately 20 percent 
decrease in proliferation in response to rAprA or rCfaD (Figure 1) (45, 46). cnrN¯ cells 
were essentially insensitive to rAprA, and this phenotype was rescued by expressing 
CnrN in the mutant background (Figure 1A). Compared to the addition of buffer, the 
addition of rCfaD to cnrN¯ cells significantly increased their proliferation (Figure 1B). 
Expressing CnrN in the cnrN¯ background blocked the ability of rCfaD to increase 
proliferation, but did not restore the ability of rCfaD to inhibit proliferation (Figure 1B). 
A combination of rAprA and rCfaD inhibited wild type proliferation similarly to either 
recombinant protein alone (Figure 1C). The response of cnrN¯ cells to the combination 
of rAprA and rCfaD mimicked their response to rCfaD alone (Figure 1C). The 
difference in the increase of proliferation of cnrN¯ cells between the addition of rCfaD 
alone and the combination of rCfaD and rAprA is statistically significant (t-test, p < 
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0.05). The proliferation of cnrN¯/CnrNOE cells was inhibited by the combination of 
rAprA and rCfaD (Figure 1C). Together, these results suggest that CnrN is necessary for 
AprA and CfaD to inhibit proliferation.   
 
cnrN¯ cells have fast proliferation  
Cells lacking AprA or CfaD proliferate faster and to a higher stationary density 
then wild-type cells (39, 40). Like aprA¯ and cfaD¯ cells, cnrN¯ cells proliferate faster, 
have a faster doubling time, and reach a higher maximum cell density than wild type 
cells (Figure 2A and Table 1). Occasionally, for unknown reasons, we observed this and 
other clones of cnrN¯ cells proliferating slower than wild type cells. There are many 
reasons a mutant might proliferate slower, such as defects in a metabolic pathway, but it 
is unusual to find clones that proliferate faster than wild type. Therefore, we believe the 
fast proliferation phenotype is the true phenotype of cnrN¯ cells. cnrN¯/CnrNOE and 
Ax2/CnrNOE cells showed no significant difference in doubling time or maximal cell 
density compared to wild type (Figure 2A and Table 1). Although cnrN¯/CnrNOE and 
Ax2/CnrNOE cells appeared to proliferate slower and to a lower cell density than cnrN¯ 
cells, only the differences between the maximum cell densities were statistically 
significant. Unlike the proliferation in liquid culture, wild type, cnrN¯, cnrN¯/CnrNOE, 
and Ax2/CnrNOE cells showed similar proliferation rates on bacteria (Figure 2B). 
Together, the data suggest that in shaking liquid culture, CnrN decreases the 
proliferation of cells.   
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Figure 1:  cnrN¯ cells are insensitive to rAprA and have altered sensitivity to rCfaD. Cell 
densities were measured after a 16-hour incubation with 300 ng/ml of rAprA or rCfaD, a 
combination of 300 ng/ml rAprA and 300 ng/ml rCfaD, or an equivalent volume of buffer. The 
percent of proliferation inhibition by (A) rAprA, (B) rCfaD, or (C) rAprA and rCfaD compared 
to the proliferation of the buffer control is shown. Values are mean ± SEM from at least three 
independent experiments. * indicates that the difference is statistically significant at p < 0.05, ** 
indicates p < 0.01, *** indicates p < 0.001, and ns indicates not significant (one-way ANOVA, 
Tukey’s test). Compared to the addition of an equal volume of buffer, the addition of rCfaD or 
the combination of rAprA and rCfaD to cnrN¯ cells significantly increased proliferation (t-test, p 
< 0.05).  
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Figure 2: CnrN affects cell proliferation. (A) Log phase cells were inoculated into HL5 media 
at 1 x 105 cells/ml and cell densities were measured daily. Values are mean ± SEM, n = 3 or 
more for all conditions. WT indicates wild type. (B) 1000 cells were plated on SM/5 plates with 
K. aerogenes bacteria and the total number of cells was determined daily. By 72 hours, cells had 
begun to overgrow the bacteria. Values are mean ± SEM, n=3 for all conditions. The absence of 
error bars indicates that the error was smaller than the plot symbol. For cells grown on bacteria, 
there were no statistically significant differences in cell density at any time between the four 
strains (1-way ANOVA, Tukey’s test). 
 
 
 
 
 21 
 
Table 1: The effect of CnrN on doubling time and stationary density of cells. Doubling times 
and stationary densities were measured for the data shown in Figure 2A. Values are mean ± 
SEM from at least 3 independent experiments. * indicates values are significantly different from 
wild-type with p < 0.05 (one-way ANOVA, Dunnett’s test). *** indicates values are 
significantly different compared to wild type with p < 0.001 (one-way ANOVA, Tukey’s test). 
The difference in maximum cell density is statistically significant between cnrN¯ and 
cnrN¯/CnrNOE with p < 0.01 and between cnrN¯ and Ax2/CnrNOE with p < 0.001 (one-way 
ANOVA, Tukey’s test). 
 
 
Cell Type Doubling time, hours 
Maximum observed cell 
density, 10
6
 cells/ml 
Wild-type 13.7 ± 1.1 20.2 ± 0.6 
cnrN¯ 10.9 ± 0.2* 27.9 ± 1.4*** 
cnrN¯/CnrNOE 12.2 ± 0.8 21.6 ± 0.7 
Ax2/CnrNOE 12.8 ± 0.5 19.8 ± 1.5 
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cnrN¯ cells secrete AprA and CfaD 
One explanation for the fast proliferation phenotype of cnrN¯ cells could be a 
decrease in extracellular accumulation of AprA or CfaD. To test this hypothesis, we 
examined the extracellular levels of AprA and CfaD in cnrN¯ and cnrN¯/CnrNOE cells. 
Both AprA and CfaD accumulate in the medium to levels that are comparable to wild-
type levels (Figure 3). Although CfaD accumulation appears to be increased in cnrN¯ 
and cnrN¯/CnrNOE cells, this increase is not significant compared to wild type 
accumulation (Figure 3D). This suggests that the fast proliferation phenotype of cnrN¯ 
cells is not due to a decrease in extracellular levels of AprA or CfaD. 
cnrN¯ cells are multinucleate 
Both aprA¯ and cfaD¯ cells tend to be multinucleate (39, 40). To determine if 
cnrN¯ cells exhibit the same phenotype, the number of nuclei per cell was measured. 
Compared to wild-type cells,  cnrN¯  cells have significantly fewer cells with one 
nucleus per cell and significantly more cells with two nuclei or three or more nuclei per 
cell (Table 2). Expression of CnrN in the cnrN¯ background partially rescued this 
phenotype. Expression of CnrN in a wild type background caused no significant change 
in the number of nuclei per cell compared to wild type. These results suggest that like 
AprA and CfaD, CnrN may be involved in cytokinesis. 
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Figure 3: Cells lacking and overexpressing CnrN secrete normal levels of extracellular 
AprA and CfaD. Conditioned media from the indicated cell lines was assayed by Western blot 
with anti-AprA (A) or anti-CfaD (B) antibodies. Data is representative of four separate 
experiments. Molecular weights in kDa are shown at the left of the blots. Asterisk indicates a 27-
kDa breakdown product of CfaD whose amount varied somewhat between cell lines and 
between experiments [5]. (C) Conditioned medium samples were run on a 4-20% PAGE gel and 
silver stained as a loading control. (D) Quantification of AprA and CfaD accumulation. 
Autoradiogram densities were normalized to the wild-type value, and are mean ± SEM. n = 4. 
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Table 2: The effect of CnrN on the number of nuclei per cell. Fluorescence microscopy was 
used to count the number of nuclei per cell (at least 200 cells for each condition) for log phase 
cells stained with DAPI. Values are mean ± SEM from at least three independent experiments. * 
indicates value is significantly different compared to wild-type value at p < 0.05, ** indicates p 
< 0.01, and *** indicates p < 0.001 (one-way ANOVA, Tukey’s test). The difference in the 
number of cells with 1 nucleus or 3 or more nuclei was significantly different between cnrN¯ 
and Ax2/CnrNOE cells with p < 0.001 and between cnrN¯/CnrNOE and Ax2/CnrN
OE cells with p < 
0.01 (one-way ANOVA, Tukey’s test). 
 
 
 Percent of cells with n nuclei 
Cell Type 1 2 3+ 
Wild-type 77.9 ± 1.8 19.0 ± 2.1 3.1 ± 0.3 
cnrN¯ 49.1 ± 4.4*** 32.2 ± 3.9* 19.3 ± 2.2*** 
cnrN¯/CnrNOE 55.6 ± 0.8*** 30.8 ± 2.1* 13.6 ± 1.9** 
Ax2/CnrNOE 74.8 ± 1.5 23.3 ± 1.0 1.8 ± 0.5 
 
 
 
 
CfaD decreases the multinucleate phenotype of cnrN¯ cells 
The addition of rCfaD to cnrN¯ cells increases their proliferation (Figure 1). One 
explanation for this increase in proliferation is that rCfaD increases the cytokinesis of 
cnrN¯ cells, which are more multinucleate than wild type cells. To test this possibility, 
wild type and cnrN¯ cells were incubated with and without rCfaD for 16 hours. After 
verifying that rCfaD decreased the proliferation of wild type cells and increased the 
proliferation of cnrN¯ cells, cells were stained with DAPI, and the nuclei per cell were 
counted. rCfaD did not cause a significant change in the nuclear phenotype of wild type 
cells. Adding rCfaD to cnrN¯ cells significantly increased the number of cells with a 
single nucleus and significantly decreased the number of cells with two nuclei and cells 
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with three or more nuclei compared to cnrN¯ cells with no rCfaD (Table 3). The 
addition of rCfaD to either wild type or cnrN¯ cells significantly decreased the number 
of nuclei per 100 cells (Table 3). Together, these data indicate that rCfaD reduces the 
multinuclearity of cnrN¯ cells, presumably by increasing cytokinesis, and this would 
account for the increase in proliferation during inhibition assays.  
 
 
 
Table 3: The effect of rCfaD on the number of nuclei per cell. Following a 16-hour 
incubation with 300 ng/ml of rCfaD or an equivalent volume of buffer, fluorescence microscopy 
was used to count the number of DAPI-stained nuclei per cell (at least 200 cells for each 
condition). Values are mean ± SEM from three independent experiments. * and *** indicate that 
values are statistically significant between – and + rCfaD for the genotype with p < 0.05 and p < 
0.001, respectively (one-way ANOVA, Tukey’s test or one-way paired t-test).  
 
 
  Percent of cells with n nuclei Nuclei/100 cells 
Cell Type rCfaD 1 2 3+  
Wild-type - 85.8 ± 2.1 13.6 ± 2.0 0.6 ± 0.4 115 ± 2 
Wild-type + 87.9 ± 1.5 11.6 ± 1.2 0.6 ± 0.4 112 ± 2* 
cnrN¯ - 50.6 ± 2.8 41.5 ± 1.7 7.9 ± 1.5 164 ± 9 
cnrN¯ + 67.1 ± 5.3* 28.6 ± 3.2* 4.3 ± 2.1* 138 ± 8*** 
 
 
 
 
CnrN does not regulate growth on a per nucleus basis 
Cell proliferation is defined as an increase in cell number, and cell growth as the 
accumulation of mass and protein (39, 40, 45, 46). Both aprA¯ and cfaD¯ cells tend to 
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be more massive than wild type, but do not accumulate mass or protein at an increased 
rate on a per nucleus basis compared to control (39, 40). This indicates that neither AprA 
nor CfaD play a role in the regulation of growth. Mass and protein content was analyzed 
in log phase cells to determine the effect of CnrN on growth. Mass, protein, and nuclei 
per 100 cells for wild type were similar to previous observations (39, 40, 45, 46). There 
was no statistically significant difference in mass between wild type, cnrN¯, 
cnrN¯/CnrNOE, or Ax2/CnrNOE cells (Table 4). Protein content and nuclei per 100 cells 
were increased compared to wild type in both cnrN¯ and cnrN¯/CnrNOE cells. Protein 
content and protein content on a per nucleus basis was decreased in Ax2/CnrNOE cells. 
On a per nucleus basis, cnrN¯ cells contained significantly less mass and protein than 
wild-type. cnrN¯/CnrNOE cells had significantly more protein content per nucleus than 
cnrN¯ cells, rescuing the mutant phenotype.   
To estimate mass, protein, and nuclei accumulation per hour, we assumed that a 
doubling in cell number also results in a doubling of mass, protein, and nuclei. We then 
divided the mass, protein, and nuclei contents for each genotype by their respective 
calculated doubling times (Table 1). On a per cell per hour basis, cnrN¯, cnrN¯/CnrNOE, 
and Ax2/CnrNOE cells accumulated mass similarly to wild-type (Table 5). Both cnrN¯ 
and cnrN¯/CnrNOE cells accumulated significantly more protein per cell per hour than 
either wild type or Ax2/CnrNOE cells. cnrN¯ and cnrN¯/CnrNOE cells accumulated 
nuclei at a faster rate than wild-type. cnrN¯/CnrNOE cells accumulated nuclei at a 
significantly slower rate compared to cnrN¯ cells, partially rescuing the fast nuclei 
accumulation of cnrN¯ cells. Ax2/CnrNOE cells accumulated nuclei at a rate similar to 
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wild type, and this rate was significantly slower than the cnrN¯ and cnrN¯/CnrNOE 
nuclei accumulation rates (Table 5). On a per nucleus basis, there were no significant 
differences in the mass and protein accumulation per hour in wild type, cnrN¯, 
cnrN¯/CnrNOE, and Ax2/CnrNOE cells. These results suggest that like AprA and CfaD, 
CnrN does not affect growth on a per nucleus basis.  
 
 
 
Table 4: The effect of CnrN on the mass and protein content of cells. Mass and protein 
content was measured, and the data from Table 2 were use to determine the number of nuclei per 
100 cells. Values are mean ± SEM from at least three independent experiments. ** indicates 
value is significantly different compared to wild type at p < 0.01 and *** indicates p < 0.001 
(one-way ANOVA, Tukey’s test). The difference in protein per 107 cells and protein per 107 
nuclei is significantly different with p < 0.001 between cnrN¯ and cnrN¯/CnrNOE and between 
cnrN¯/CnrNOE and Ax2/CnrNOE. The difference in protein per 107 cells is significantly different 
between cnrN¯ and Ax2/CnrNOE with p < 0.001. Both cnrN¯ and cnrN¯/CnrNOE nuclei per 100 
cells are significantly different from Ax2/CnrNOE with p < 0.001.  
 
 
 Per 107 cells  Per 107 nuclei 
Cell type 
Mass 
(mg) 
Protein (mg) Nuclei/100 
cells 
Mass (mg) Protein (mg) 
Wild-type 10.3 ± 0.4 0.86 ± 0.02 126 ± 1 8.2 ± 0.3 0.68 ± 0.02 
cnrN¯ 9.0 ± 0.4 0.97 ± 0.01** 187 ± 7*** 4.8 ± 0.2*** 0.52 ± 0.02** 
cnrN¯/CnrNOE 11.2 ± 1.0 1.30 ± 0.04*** 170 ± 4*** 6.6 ± 0.6 0.76 ± 0.03 
Ax2/CnrNOE 9.4 ± 1.3 0.70 ± 0.02*** 131 ± 6 7.1 ± 0.9 0.53 ± 0.02** 
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Table 5: The effect of CnrN on mass and protein accumulation of cells. Mass, protein, and 
nuclei values from Table 4 were divided by the doubling time for each respective genotype from 
Table 1. Values are mean ± SEM from at least three independent experiments. * indicates value 
is significantly different compared to wild-type value at p < 0.05 and *** is significant at p < 
0.001 (one-way ANOVA, Tukey’s test). The difference in protein per cell per hour is 
significantly different between cnrN¯ and Ax2/CnrNOE and between cnrN¯/CnrNOE and 
Ax2/CnrNOE with p < 0.01 and p < 0.001, respectively. The differences in nuclei per 107 cells per 
hour are significantly different between cnrN¯ and cnrN¯/CnrNOE, cnrN¯ and Ax2/CnrNOE, and 
cnrN¯/CnrNOE and Ax2/CnrNOE with p < 0.001. The difference in protein per 107 nuclei per hour 
is significantly different between cnrN¯/CnrNOE and Ax2/CnrNOE with p < 0.05. 
 
 
 Per 107 cells/hour  Per 107 nuclei/hour 
Cell type Mass (mg) Protein (µg) Nuclei, x 10
-5
 Mass (mg) Protein (µg) 
Wild-type 0.75 ± 0.07 62.6 ± 5.4 9.2 ± 0.77 0.60 ± 0.05 50 ± 4 
cnrN¯ 0.82 ± 0.04 88.6 ± 2.1* 17 ± 0.47*** 0.44 ± 0.02 47 ± 1 
cnrN¯/CnrNOE 0.92 ± 0.10 107 ± 7.4*** 14 ± 0.94*** 0.54 ± 0.06 63 ± 5 
Ax2/CnrNOE 0.87 ± 0.08 54.2 ± 2.5 10 ± 0.61 0.67 ± 0.07 41 ± 3 
 
 
 
 
CnrN affects spore viability 
Cells lacking AprA and CfaD have reduced spore viability (39, 40). cnrN¯ cells 
were examined for their ability to form detergent-resistant spores. An equivalent number 
of wild-type, cnrN¯, cnrN¯/CnrNOE, and Ax2/CnrNOE cells were developed, the spores 
were collected, and dilutions of detergent-treated spores were plated. The numbers of 
cells with a spore morphology and the numbers of detergent-resistant spores from cnrN¯ 
cells was significantly less compared to those recovered from wild type (Table 6). 
Expression of CnrN in the cnrN¯ background rescued the number of detergent-resistant 
spores and appeared to partially rescue the number of visible spores. The number of 
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recovered spores and the number of viable spores from cnrN¯/CnrNOE or Ax2/CnrNOE 
cells were similar to wild type levels. These data indicate that like AprA and CfaD, 
CnrN affects the ability of cells to form viable spores. 
 
 
 
 
Table 6: The effect of CnrN on spore viability. Cells were developed on filter pads for 48 
hours and the percent of visible spores was calculated as a percent of input cells. Detergent-
treated spores were plated and analyzed for their ability to produce colonies. Values are mean ± 
SEM from at least three independent experiments. ** and *** indicates differences are 
significantly different compared to wild-type with p < 0.01 and p < 0.001, respectively (one-way 
ANOVA, Tukey’s test). The difference in the number of visible spores between cnrN¯ and 
Ax2/CnrNOE is significantly different with p < 0.01. The difference in the number of detergent-
resistant spores between cnrN¯ and cnrN¯/CnrNOE is significantly  different with p < 0.05. The 
number of detergent-resistant spores in Ax2/CnrNOE is significantly different from both cnrN¯ (p 
< 0.001) and cnrN¯/CnrNOE (p < 0.05).  
 
 
Cell type 
Number of spores after development 
as a percent of input cell number 
Detergent-resistant spores as a 
percent of total spores 
Wild-type 100 ± 12    83.3 ± 6.3 
cnrN¯        41.3 ± 8.0**          37.8 ± 2.5*** 
cnrN¯/CnrNOE   59.9 ± 2.6  66.5 ± 15 
Ax2/CnrNOE 109 ± 11 107 ± 16 
 
 
 
AprA and CfaD affect CnrN localization 
 PTEN can translocate from the cytosol to the inner face of the plasma membrane 
in response to extracellular signals (111). We observed CnrN localization at the 
periphery of cells, in the interior of cells, and on vesicle-like structures in the interior of 
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cells (132). To test whether CnrN translocates in response to extracellular AprA or 
CfaD, we examined the localization of myc-tagged CnrN in the cnrN¯ mutant 
background. Since both the ectopically expressed CnrN and our recombinant proteins 
are myc-tagged, we used immunoblotting of partially purified membranes to specifically 
examine CnrN levels. Log-phase cnrN¯/CnrNOE cells were stimulated with rAprA, 
rCfaD, a mix of rAprA and rCfaD, or buffer for 10 and 20 minutes. The cells were then 
lysed, and Western blots of the membranes were stained with antibodies against the myc 
tag. At ten minutes after stimulation, all conditions showed similar amounts of 
membrane-associated myc-CnrN compared to the zero time point (Figure 4). After 20 
minutes of stimulation with AprA alone or CfaD alone, there was no significant effect on 
the amount of membrane-associated myc-CnrN (Figure 4). A significant increase in 
membrane-associated myc-CnrN was observed at 20 minutes when cells were stimulated 
with both AprA and CfaD (Figure 4). For unknown reasons, the amount of membrane-
associated myc-CnrN decreased at 20 minutes in the buffer control (Figure 4). These 
results suggest that AprA and CfaD together can induce localization of CnrN to the 
membrane.  
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Figure 4: CnrN localization. Myc-tagged cnrN¯/CnrNOE cells were incubated with rAprA, 
rCfaD, both rAprA and rCfaD, or an equivalent volume of buffer and lysed at the indicated 
times. Membranes from the lysates were collected by centrifugation and were analyzed for the 
presence of myc-tagged CnrN by Western blotting and staining for the myc-tag. Band intensities 
were measured as a ratio of the zero time point. Values are mean ± SEM, n = 3 or more. * and 
*** indicate a significant difference with p < 0.05 or p < 0.001, respectively, compared to the 
zero time point (t-test). Membrane samples were run on a 4-20% PAGE gel and coomassie 
stained as a loading control. 
 
 
 
CnrN is necessary for chemorepulsion by AprA 
 We previously characterized AprA as a chemorepellent of Dictyostelium cells 
(48). To determine if CnrN is necessary for chemorepulsion by AprA, we used Insall 
chambers (48, 133) to analyze the response of cnrN¯ cells to rAprA. The forward 
migration index represents the displacement of cells along a gradient as a fraction of the 
total cell movement. A negative forward migration index indicates displacement away 
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from rAprA. The chemorepulsion of wild type cells away from rAprA was similar to 
previous observations (48). cnrN¯ cells were not chemorepulsed in a gradient of AprA, 
and expressing CnrN in the mutant background rescued this defect (Figure 5). This 
indicates that CnrN is required for AprA to act as a chemorepellent of Dictyostelium 
cells.  
 
 
 
 
 
Figure 5: CnrN is necessary for chemorepulsion by AprA. Cells were assayed for 
chemorepulsion in response to rAprA in an Insall chamber for 1 hour. A negative migration 
index indicates movement away from the AprA source. Values are mean ± SEM of at least three 
independent experiments. * (p < 0.05) and ** (p < 0.01) indicate a significant difference (t-test).  
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Discussion 
Extracellular AprA and CfaD inhibit Dictyostelium cell proliferation and 
extracellular AprA causes cell chemorepulsion (40, 41, 48). cnrN¯ cells are insensitive 
to both the proliferation-inhibiting and chemorepellent effects of rAprA, and these 
phenotypes are rescued by expressing CnrN in cnrN¯ cells. Like aprA¯ and cfaD¯ cells, 
cnrN¯ cells have a faster doubling time and reach a higher cell density than wild type 
cells, have similar mass and protein accumulation per nucleus, and form less viable 
spores. Like aprA¯ and cfaD¯ cells, cnrN¯ cells are also more multinucleate than wild 
type cells. Interestingly, adding rCfaD to cells lacking CnrN increases proliferation. The 
increase in proliferation of cnrN¯ cells in response to rCfaD appears to be due to an 
increase in cytokinesis. The significant difference in the increase of cnrN¯ cell 
proliferation between the combination of rAprA and rCfaD, and rCfaD alone, suggests a 
cooperative role between AprA and CfaD. If AprA and CfaD function independently, 
cnrN¯ cells would respond to the combination of rAprA and rCfaD similarly to rCfaD 
alone, since cnrN¯ cells are insensitive to rAprA signaling. Thus, the presence of AprA 
decreases the ability of CfaD to increase the proliferation of cnrN¯ cells. Together, the 
data suggest that CnrN is required for  AprA and CfaD to inhibit proliferation. 
PTEN-like phosphatases are recruited to the plasma membrane to 
dephosphorylate PIP3 to PIP2 (113, 125-128). CnrN is localized in the cytosol, in 
vesicle-like structures, and at the plasma membrane. PTEN binds to 
phosphoserine/phosphocholine lipid vesicles via the C2 domain of the protein (134). 
Since CnrN contains a putative PTEN-like C2 domain (115), CnrN may also bind to 
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vesicles containing phosphoserine and phosphocholine. We found that CnrN localization 
is increased on membranes in response to a mixture of rAprA and rCfaD after 20 
minutes. AprA and CfaD may recruit CnrN to the membrane to inhibit proliferation-
promoting factors. In addition, AprA may also utilize CnrN membrane recruitment to 
potentiate chemorepulsion of Dictyostelium cells. CnrN is a necessary component of the 
AprA chemorepellent pathway. During chemotaxis, PTEN inhibits the formation of 
pseudopods at the trailing end of a cell (38, 58, 62). In the AprA chemorepellent system, 
the PTEN-like phosphatase CnrN may be recruited to the membrane adjacent to the 
source of AprA. This would then inhibit the formation of pseudopods in the direction of 
the AprA source, allowing cells to move away from the source of AprA.  
Together, our results indicate that CnrN is recruited to the membrane in response 
to a combination of AprA and CfaD, acts as a negative regulator of proliferation, and 
mediates AprA-induced chemorepulsion. An intriguing possibility is that in higher 
eukaryotes, factors that slow proliferation and/or act as chemorepellents may also 
regulate the localization of PTEN or PTEN-like phosphatases.  
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CHAPTER III 
DIPEPTIDYL-PEPTIDASE IV IS A HUMAN AND MURINE NEUTROPHIL 
CHEMOREPELLENT
1
 
 
Summary  
 In Dictyostelium discoideum, AprA is a secreted protein that inhibits proliferation 
and causes chemorepulsion of Dictyostelium cells, yet AprA has little sequence 
similarity to any human proteins. We found that a predicted structure of AprA has 
similarity to human dipeptidyl-peptidase IV (DPPIV). DPPIV is a serine protease 
present in extracellular fluids that cleaves peptides with a proline or alanine in the 
second position. In Insall chambers, DPPIV gradients below, similar to, and above the 
human serum DPPIV concentration cause movement of human neutrophils away from 
the higher concentration of DPPIV. A 1% DPPIV concentration difference between the 
front and back of the cell is sufficient to cause chemorepulsion. Neutrophil speed and 
viability are unaffected by DPPIV. DPPIV inhibitors block DPPIV-mediated 
chemorepulsion. In a murine model of acute respiratory distress syndrome (ARDS), 
aspirated bleomycin induces a significant increase in the number of neutrophils in the 
lungs after 3 days. These results indicate that DPPIV functions as a chemorepellent of  
 
_______________________________ 
1 Reprinted with permission. Originally published in The Journal of Immunology. Herlihy SE, Pilling D, 
Maharjan AS, Gomer RH. 2013. Dipeptidyl Peptidase IV Is a Human and Murine Neutrophil 
Chemorepellent. J. Immunol. 190: 6468-6477. Copyright © 2013 The American Association of 
Immunologists, Inc. http://www.jimmunol.org/ 
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human and mouse neutrophils, and suggest new mechanisms to inhibit neutrophil 
accumulation in ARDS.   
 
Introduction 
 Chemotaxis is the directed movement of cells due to a gradient of an attractant or 
repellent. Chemotaxis has been observed in both prokaryotes and eukaryotes (56, 135). 
In humans, neutrophils show chemotaxis towards bacterial products such as N-formyl-
methionine-leucine-phenylalanine (fMLP), and towards signals secreted by macrophages 
and epithelial cells such as interlukin-8 (IL-8) (54, 55). A large number of 
chemoattractants have been characterized, while relatively few chemorepellents have 
been identified (64, 67, 68, 136-138).  
Dictyostelium cells secrete two proteins, AprA and CfaD, which inhibit 
Dictyostelium cell proliferation (39, 40). Although CfaD has sequence similarity to 
cathepsin L, AprA shows no significant sequence similarity to eukaryotic proteins (39, 
40). We found that AprA also functions as a chemorepellent of Dictyostelium cells (48). 
Wild-type cells in a colony rapidly move away from the dense colony center, while 
AprA knock-out cells show no directional movement away from the center of a colony 
(46, 48). When wild-type cells are placed in a gradient of recombinant AprA (rAprA), 
cells show a biased movement away from rAprA (48).  
 
 37 
 
 Protein structure prediction can be highly accurate and reveal new functions of a 
protein (139-144). The protein prediction server I-TASSER uses a multi-step process to 
predict protein structure (139, 141). First, initial models of the structure are generated 
from the amino acid sequence (139, 141). The models are then adjusted using Monte 
Carlo simulations to identify folds with the lowest free energy (139, 141). Finally, 
spatial constraints and optimal hydrogen bindings are used to adjust the predicted 
structure (139, 141). The predicted structure can then be used to search for proteins with 
similar structures (140, 142-144). 
 Dipeptidyl-peptidase IV (DPPIV) is a 110 kDa serine protease that cleaves 
peptides with a proline or alanine in the second position at the N-terminus (145). DPPIV 
is on the extracellular surface of some lymphocytes and epithelial cells, and a heavily 
glycosylated soluble form of DPPIV is also found in plasma, serum, cerebrospinal fluid, 
synovial fluid, semen, and urine (75, 76). DPPIV degrades glucagon-like peptide-1 
(GLP-1) (83). Drugs that block DPPIV activity also block this degradation, and are used 
to treat type 2 diabetes (83). By activating or deactivating peptide signals, DPPIV affects 
a large variety of signaling molecules regulating chemotaxis, tissue remodeling, cell 
adhesion, and other processes (81, 146).  
Using the I-TASSER program, we identified structural similarity between 
Dictyostelium AprA and human DPPIV. We show that neutrophils are chemorepulsed by 
DPPIV, and that this chemorepulsion is dependent on the enzyme activity of DPPIV. In 
an in vivo model of neutrophil movement, oropharyngeal aspiration of DPPIV reduces 
neutrophil accumulation in the lungs of bleomycin-treated mice. In this report, we show 
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that DPPIV acts as a chemorepellent of human neutrophils and present a new potential 
method to inhibit neutrophil accumulation in tissues. 
 
Materials and Methods 
Structure prediction, alignment, and superimposition 
The tertiary structure of AprA was predicted using I-TASSER (139-141). The 
PDB file of the predicted AprA structure was input into the Dali server to find similar 
protein structures and calculate structural similarities (147). The structure of AprA and 
DPPIV were superimposed using pairwise alignment (http://agknapp.chemie.fu-
berlin.de/gplus/) (148, 149).  
 
Neutrophil isolation 
Blood was collected from healthy volunteers with specific approval from the 
Institutional Review Board of Texas A&M University. Written consent was received, 
and all samples were de-identified before analysis. Neutrophils were isolated from the 
blood using Lympholyte-poly (Cedarlane Laboratories, Hornby, Canada) following the 
manufacturer’s directions and resuspended in 2% BSA (Fraction V, A3059, Sigma) in 
RPMI-1640 (Lonza). 
Neutrophils were further purified using negative selection, as described 
previously (150). Briefly, neutrophils were depleted of eosinophils, monocytes, and 
lymphocytes by incubating the cells for 10 minutes at room temperature with 5 µg/ml of 
anti-human CD244 (Biolegend), and then depleting CD244 positive cells with Pan 
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Mouse IgG Dynabeads (Invitrogen). Cells were resuspended to a final volume of 1 ml in 
2% human-albumin-RPMI. 
To determine the purity of CD244-depleted neutrophil preparations, cells were 
resuspended in PBS containing 2% BSA and cell smears were prepared as described 
previously (151). Cells smears were air dried overnight, fixed in methanol, stained with 
hematoxylin and eosin, and cell morphology was determined by microscopy, as 
described previously (150).  
Human albumin was isolated from human serum (Lonza) using Affi-gel Blue Gel 
beads (BioRad). After washing beads three times with phosphate buffered saline, beads 
were incubated with serum at room temperature for 2 hours. Beads were collected by 
centrifugation at 300 x g for 2 minutes and washed with buffer (20 mM Tris, 140 mM 
NaCl, 2 mM calcium) and the albumin eluted off overnight with 500 mM NaCl. 
Albumin was then concentrated and buffer exchanged to Earl’s balanced salt solution 
(Sigma) using a 10 kDa centrifugal filter (Millipore) and stored at 4°C.  
 
Insall chamber assays 
Recombinant human soluble DPPIV (rDPPIV) was purchased from Enzo 
Lifesciences. To measure the effect of DPPIV on cell displacement, we used Insall 
chambers, which allows direct visualization of cell movement, as described previously 
for melanoma cells, Dictyostelium, and neutrophils (48, 133, 152). Briefly, 22 x 22mm 
glass cover slips were etched with 1 M HCl, rinsed with deionized water, and coated 
with 20 µg/mL bovine plasma fibronectin (Sigma) for 30 minutes at 37°C. Cover slips 
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were then washed twice with PBS, and 300 µl of neutrophils at 5 x 106 cells/ml were 
allowed to adhere to the coverslip for 15 minutes at 37°C. We then utilized an Insall 
chamber slide, a kind gift from Robert Insall (133). Two concentric depressions and the 
separating bridge were filled with 2%BSA-RPMI. The media was removed from the 
coverslips, which were then placed face down on the chamber. Media was then removed 
from the outer chamber and was replaced by DPPIV alone, DPPIV inhibitor alone 
(Diprotin A, Enzo Lifesciences or DPPI 1c hydrochloride, Tocris), DPPIV plus DPPIV 
inhibitor (all in 2%BSA-RPMI), or 2%BSA-RPMI. Cells located on the bridge between 
the square depressions were then filmed as previously described (153), using a 10X 
objective for 1 hour at 37°C in a humidified 5% CO2 incubator. Displacement of at least 
10 randomly chosen cells per experiment was measured over periods of 10 minutes. Cell 
tracking and track analysis was done as previously described (48) with the exception that 
videos of an hour in length were processed into 10 minute segments to yield a TIFF 
stack of 47 images for analysis (with 13-second intervals between images). Insall 
chamber assays for pure neutrophils were done with the same procedures expect that 
coverslips were coated with 20 µg/mL human plasma fibronectin (Trevigen) and 2% 
human albumin-RPMI was used instead of 2% BSA-RPMI.  
For conditioned media assays, neutrophils at 5 x 106 cells/ml were incubated with 
300 ng/ml DPPIV or an equivalent volume of buffer for 30 minutes at 37°C in tubes that 
were pre-coated with 4% BSA-RPMI. Where indicated, the DPPIV inhibitor DPPI 1c 
hydrochloride was added to the conditioned medium to a final concentration of 200 nM. 
Cells were collected by centrifugation at 500 x g for 5 minutes and the supernatant was 
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added to the outside chamber of an Insall chamber. Cells were filmed as described 
above. Samples of conditioned media were separated on 4-20% PAGE gels (BioRad), 
transferred to Immobilon P membranes (Millipore), and membranes were stained with 
100 ng/ml anti-human DPPIV antibodies (R&D Systems).   
 
Effect of DPPIV peptidase activity on albumin stability 
 2% BSA-RPMI and 2% human albumin-RPMI were incubated with 300 ng/ml 
rDPPIV or an equivalent volume of buffer for 3 hours. Samples were taken at 0, 15, 30, 
45, 60, and 180 minutes, mixed with SDS sample buffer, separated on 4-20% PAGE, 
and then silver stained.  
 
Neutrophil influx in mice 
4-week-old C57/BL6 mice (Jackson, Bar Harbor, ME) were treated with an 
oropharyngeal aspiration of 50 μl of saline or 3U/kg bleomycin (Calbiochem) (154). The 
successful aspiration of bleomycin into the lungs was confirmed by listening for the 
crackling noise heard after the aspiration. 24 hours following bleomycin aspiration (day 
1), mice were treated with an oropharyngeal aspiration of 50 μl of 0.9% saline with 0.9 
µg rDPPIV (Enzo Lifesciences) or an equal volume of 0.9% saline. Mice were weighed 
daily and euthanized at day 3 after bleomycin aspiration. Blood was collected by cardiac 
puncture from the euthanized mice and blood glucose was measured using Accu-check 
Active (Roche). The lungs were perfused with 300 μl of PBS three times to collect cells 
by bronchoalveolar lavage (BAL) as described previously (155). The primary BAL cells 
 42 
 
were collected by centrifugation at 500 x g for 10 minutes. Primary BAL pellets were 
resuspended in the secondary and tertiary BAL fluid and the combined cells were 
collected by centrifugation at 500 x g for 5 minutes. The cells were resuspended in 500 
μl of 4% BSA-PBS and counted with a hemocytometer. 100 μl of diluted cells was then 
aliquoted into cytospin funnels and spun onto glass slides (Superfrost plus white slides, 
VWR, West Chester, PA) at 400 rpm for 5 minutes using a cytospin centrifuge 
(Shandon, Cheshire, England). These cells were then air-dried, and stained with Gill’s 
haematoxylin. Greater than 200 cells were counted for total cell number and neutrophils, 
macrophages, and lymphocytes were identified by morphology. The percent of 
neutrophils, macrophages, or lymphocytes was then multiplied by the total number of 
cells recovered from the BAL to obtain the number of each cell type in the BAL. The 
mice were used in accordance with guidelines published by the National Institutes of 
Health, and the protocol was approved by the Texas A&M University Animal Use and 
Care Committee. 
 
Immunohistochemistry 
After BAL, lungs were inflated with pre-warmed OCT (VWR) and then 
embedded in OCT, frozen on dry ice, and stored at -80°C as described previously (156). 
Lung tissue sections (5 μm) were prepared and immunohistochemistry was done as 
described previously (156) except slides were incubated with 5 μg/ml primary antibodies 
in 4% BSA-PBS for 60 minutes. Active caspase-3 staining was done overnight at 4°C. 
The lung sections were stained for Ly6G (BD Biosciences) to detect neutrophils, CD11b 
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(BioLegend) to detect infiltrating macrophages and neutrophils, CD11c (MBL) to detect 
lung resident macrophages and dendritic cells, CD206 (Biolegend) to detect the mannose 
receptor on macrophages and dendritic cells, and CD107b (Mac3) (Biolegend) to detect 
alveolar and tissue macrophages and granulocytes, cleaved caspase-3 (Cell Signaling 
Technologies) to detect activated caspase-3, and isotype-matched mouse or rabbit 
irrelevant antibodies as controls. Slides were then washed three times with PBS over 30 
minutes and incubated with 5 μg/ml biotinylated mouse F(ab’)2 anti-rat IgG or 5 μg/ml 
biotinylated donkey F(ab’)2 anti-rabbit IgG in 4% BSA-PBS for 30 minutes. Slides were 
then washed three times in PBS over 30 minutes and incubated with a 1:500 dilution of 
streptavidin alkaline phosphatase (Vector Laboratories) in 4% BSA-PBS for 30 minutes. 
Staining was developed with a VectorRed Alkaline Phosphatase Kit (Vector 
Laboratories) for 10 minutes. Slides were then mounted as described previously (156). 
Five or ten 450 µm fields of view were counted for Ly6G-stained or active caspase-3-
stained positive cells, respectively. Areas containing large blood vessels and bronchioles 
were excluded from analysis.  
 
Neutrophil survival 
Isolated neutrophils were cultured in RPMI-1640 containing 10% (v:v) fetal 
bovine serum and 2 mM glutamine in 96-well tissue-culture plates at 37°C for 20 hours, 
as described previously (157). Neutrophils were cultured in the presence or absence of 
25 ng/ml human IL-8 or human TNF-α (both from Peprotech), or 400 ng/ml DPPIV. 
After 20 hours neutrophils were labeled with annexin V (BioLegend) and propidium 
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iodide (Sigma) according to the manufacturer’s instructions, to identify early and late 
stages of cell death. In addition, cytospin preparations were used to assess for 
morphological changes associated with apoptosis, as described previously (157-159).  
 
Statistics 
 Statistics were done using Prism (GraphPad Software, San Diego, CA). One-way 
ANOVA was used to compare between multiple groups and Student’s t-test was used to 
compare between two groups. 
 
Results 
AprA has structural similarity to the human protein dipeptidyl-peptidase IV 
 AprA has little sequence similarity to any mammalian protein (39). Using I-
TASSER, we generated a predicted structure for AprA (Figure 6). The Dali Server, used 
to compare protein structures, composes a list of the proteins with the most structural 
similarity to the query protein. The proteins with the top structural similarities to the 
predicted structure of AprA were Cephalosporin C deacetylase (a β-lactamase from the 
fungus Acremonium), acetyl xylan esterase (from the bacteria Bacillis pumilus, cleaves 
carboxyl-ester bonds), acylamino-acid-releasing-enzyme (from the Archaea Aeropyrum 
pernix K1, cleaves acylated terminal amino acids), and dipeptidyl-peptidase IV (DPPIV) 
(human soluble form, cleaves terminal amino acids with proline or alanine in the second 
position). AprA has an 11% structural identity to the entire structure of soluble human 
DPPIV (Figure 6, the α/β hydrolase domain of DPPIV is shown). Since DPPIV, like 
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AprA, can be found as an extracellular protein, these results suggested that AprA might 
have functional similarity to DPPIV or vice versa.  
 
 
 
 
 
Figure 6: Superimposition of the predicted structure of AprA with the structure of the α/β 
hydrolase domain of human DPPIV. The catalytic domains of DPPIV (the α/β hydrolase 
domain of PDB ID 1J2E), and AprA (predicted structure) were superimposed and the catalytic 
triads highlighted. The α/β hydrolase domain of DPPIV is shown in green and its catalytic triad 
(Asp708, His740, and Ser630) is orange. The predicted structure of AprA is shown in cyan and 
its potential catalytic triad (Asp288, His319, and Ser195) is blue. The β-propeller domain of 
DPPIV was removed for simplicity since the predicted structure of AprA had no overlap with 
this domain.  
 
 
Neutrophils show biased movement away from a source of DPPIV 
 AprA functions as a chemorepellent of Dictyostelium cells (48). Dictyostelium 
and neutrophils share many properties of chemotaxis (160, 161). Therefore, we 
hypothesized that DPPIV may regulate human neutrophil motility due to its structural 
similarity to AprA. To examine neutrophil chemotaxis in gradients of DPPIV, we used 
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an Insall chamber. When neutrophil movement was tracked over 10 minute periods, 
there was no bias of movement in the media control (Figure 7A and Figure 8). A biased 
movement away from a source of DPPIV was observed (Figure 7B and Figure 8). Cells 
were tracked and the average center of mass observed for the endpoints of cells in each 
population was determined. The center of mass of cell endpoints showed displacement 
away from the source of DPPIV (Figure 7 and Figure 8). The concentration of DPPIV in 
human blood ranges from 400 to 800 ng/ml, or 4.7 to 9.4 nM (162, 163). Therefore, we 
tested the ability of DPPIV to affect neutrophil migration above, below, and within this 
concentration range. Neutrophils showed biased movement away from higher 
concentrations of rDPPIV in a variety of DPPIV concentration gradients (Table 7). An 
equal concentration of DPPIV in both wells of the chamber resulted in no biased 
directional movement of neutrophils (Table 7). The presence of DPPIV affected 
directionality, although not in any systematic manner (Table 7). Because we used 
different sets of donors for each gradient concentration, the directionality in the media 
controls vary somewhat within the different sets of experiments. TNF-α stimulated 
neutrophils also migrated away from DPPIV (Table 7). For unknown reasons, some of 
the cells appeared to move towards the higher concentration of DPPIV. In Figure 7B, 
two such cells can be seen. The fraction of cells exhibiting this anomalous behavior was 
not obviously affected by the amount of DPPIV in the gradient (Table 7). Combined, 
these data indicate that a gradient of DPPIV causes chemorepulsion of neutrophils.  
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Figure 7: Human neutrophils show biased movement away from rDPPIV. Neutrophil 
migration was measured in the A) absence or B) presence of a 0-1.2 nM rDPPIV gradient. 
Neutrophils were filmed and tracked (see Methods and Materials) over 10-minute periods. 
Orientation is such that the source of rDPPIV is on the left. Graphs are data from one of three 
independent experiments (see Figure 8 for the other two experiments). Red dots represent the 
average center of mass for the ending positions of all cells.  
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Figure 8: Human neutrophils show biased movement away from rDPPIV. Neutrophil 
migration was measured in the absence (left two panels) or presence (right two panels) of a 0-1.2 
nM rDPPIV gradient. Neutrophils were filmed and tracked over 10-minute periods. Orientation 
is such that the source of rDPPIV is on the left. Graphs show the remaining two replicates from 
Figure 3. Red dots represent the average center of mass for all the ending positions of all cells.  
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Table 7: The effect of DPPIV on forward migration and directness of neutrophil movement. The 
data from at least three independent sets of cell population tracks (see Figure 7 and 8 as an 
example) were analyzed to determine the forward migration index (FMI) and directionality. FMI 
is a measure of migration of cells along the gradient, where zero equals no movement, a positive 
number equals movement away from the source, and a negative number indicates movement 
toward the source. Directionality is the ratio of Euclidean distance to accumulated distance. For 
each gradient, neutrophils from at least three different volunteers were used. * indicates p < 0.05, 
** indicates p < 0.01, and *** indicates p < 0.001 compared to the media control (t-test). TNF 
represents a gradient of DPPIV with TNF-α stimulated neutrophils. N/A indicates not applicable. 
 
 
 
 
 
DPPIV gradients affect the probability of directional movement but do not affect cell 
speed  
 We also examined the ability of DPPIV to affect cell speed and directional 
movement using the cell-tracking data. A gradient of DPPIV did not affect cell speed, 
and speeds were consistent with previous measurements of neutrophil migration (Table 
 Forward Migration Index Directionality Number 
of cells 
moving 
toward 
DPPIV 
rDPPIV 
gradient 
(nM) 
Media 
control  
(0 nM 
rDPPIV) 
rDPPIV 
Media 
control 
(0 nM 
rDPPIV) 
rDPPIV rDPPIV 
      0-1.2  0.00 ± 0.03    0.21 ± 0.03*** 0.35 ± 0.02 0.39 ± 0.02* 10 / 93 
      0-3.5 -0.04 ± 0.04    0.21 ± 0.06*** 0.26 ± 0.02     0.50 ± 0.03*** 9 / 55 
 0-11.7  0.01 ± 0.06    0.15 ± 0.05* 0.47 ± 0.03      0.47 ± 0.02 6 / 50 
  4.7-4.7  0.01 ± 0.06   -0.01 ± 0.04 0.47 ± 0.03      0.30 ± 0.02*** N/A 
   4.7-11.7 -0.02 ± 0.06    0.22 ± 0.06** 0.50 ± 0.03 0.42 ± 0.04* 4 / 32 
 9.4-23 -0.01 ± 0.05    0.13 ± 0.05* 0.36 ± 0.03    0.50 ± 0.02*** 25 / 74 
    0-3.5
TNF
 -0.02 ± 0.03  0.10 ± 0.03** 0.32 ± 0.02     0.34 ± 0.02 8 / 81 
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8), and were similar to neutrophil speed observed in gradients on fMLP in an Insall 
chamber (30.2 ± 3.6) (164, 165). PA and PT can be defined as the probability that a cell 
would move away or toward a source of DPPIV, respectively in a 13-second interval 
(48). In gradients of DPPIV, with the exception of a 9.4-23 nM gradient, either PT was 
significantly less or PA was significantly more than the control (Table 9). The probability 
of a cell moving toward or away from DPPIV was similar to the control when equal 
concentrations were present on either side of the chamber (Table 9). DPPIV did not 
significantly affect P0, the probability that a cell did not move in a 13-second interval. 
These results indicate that although a gradient of DPPIV does not significantly affect cell 
speed, it does affect the movement of a cell toward or away from the source of DPPIV.  
 
 
 
 
Table 8: The effect of DPPIV on the average speed of neutrophils. The data from at least 
three independent sets of cell population tracks (see Figure 7 and Figure 8) were used to 
determine the average speed of neutrophils. Values are mean ± SEM, n = 3 or more.  
  
Average Cell Speed (µm/minute) 
rDPPIV  
gradient (nM) 
Media control 
(0 nM rDPPIV) 
rDPPIV 
0-1.2 27 ± 1 26 ± 1 
0-3.5 23 ± 1 23 ± 1 
0-11.7 24 ± 2 25 ± 2 
4.7-4.7 17 ± 1 16 ± 1 
4.7-11.7 17 ± 1 18 ± 2 
9.4-23 17 ± 1 17 ± 1 
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Table 9: Percentage of cells in the population moving in a biased direction over 10 min. The 
data from at least three independent sets of cell population tracks (see Figure 7 and Figure 8 for 
an example) were used to determine the probability of cell movement toward or away from the 
source of DPPIV. PA and PT are the probabilities that a cell would move away from or toward the 
source of DPPIV, respectively in a 13-second interval. P0 is the probability that a cell will not 
move. PA and PT are statistically significantly different in all DPPIV gradients at p < 0.05 (t-test), 
except for 0-11.7 nM DPPIV, which is significant at p < 0.01. In the controls, PA and PT are 
statistically significant only in the 4.7-11.7 and 9.4-23 nM controls (p < 0.05). TNF represents a 
gradient of DPPIV with TNF-α stimulated neutrophils.  
 
 
rDPPIV 
concentrati
on 
gradient 
(nM) 
P0 PT PA 
 Control rDPPIV Control rDPPIV Control rDPPIV 
0-1.2  0.39 ± 0.14 0.54 ± 0.02 0.32 ± 0.08   0.16 ± 0.01* 0.29 ± 0.06 0.31 ± 0.02 
0-3.5  0.27 ± 0.13 0.28 ± 0.08 0.39 ± 0.08 0.27 ± 0.04 0.34 ± 0.06   0.45 ± 0.06* 
  0-11.7 0.10 ± 0.03 0.13 ± 0.06 0.46 ± 0.01   0.35 ± 0.02* 0.44 ± 0.03 0.52 ± 0.05 
   4.7-4.7 0.17 ± 0.07 0.20 ± 0.05 0.44 ± 0.03 0.43 ± 0.03 0.39 ± 0.04 0.37 ± 0.03 
     4.7-11.7 0.19 ± 0.06 0.22 ± 0.06 0.44 ± 0.03   0.26 ± 0.05* 0.38 ± 0.04   0.53 ± 0.02* 
  9.4-23 0.29 ± 0.02 0.22 ± 0.06 0.39 ± 0.03 0.38 ± 0.03 0.33 ± 0.02 0.40 ± 0.08 
     0-3.5
TNF
 0.26 ± 0.04 0.26 ± 0.03 0.38 ± 0.04 0.31 ± 0.03 0.36 ± 0.01   0.43 ± 0.02* 
 
 
 
 
 
 
 
 52 
 
Neutrophil chemorepulsion is sensitive to DPPIV enzyme inhibitors 
DPPIV enzyme activity has been implicated in the chemotaxis of several types of 
immune cells through cleavage of human chemokines (84, 146, 166, 167). To determine 
if DPPIV enzyme activity affects DPPIV-induced neutrophil chemorepulsion, we used 
two enzyme inhibitors of DPPIV, Diprotin A and DPPI 1c hydrochloride (DPPI 1cHCl) 
(168, 169). The inhibitors alone caused no attraction or repulsion of human neutrophils 
(Figure 9). When either of the inhibitors was added with DPPIV, the chemorepulsion of 
neutrophils away from the source of DPPIV was significantly reduced compared to 
DPPIV alone (Figure 9). This suggests that DPPIV inhibitors block the ability of DPPIV 
to induce neutrophil chemorepulsion.  
 
 
 
 
 
Figure 9: Inhibitors of DPPIV reduce the chemorepulsion of neutrophils away from 
DPPIV. The forward migration index is shown for a gradient of DPPIV, fMLP, two DPPIV 
inhibitors, or DPPIV with the inhibitors. Values are mean ± SEM, n = 3. * indicates a significant 
difference compared to a gradient of DPPIV (p < 0.05 by t-test).    
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DPPIV does not appear to cleave albumin 
 Several possibilities exist to explain why DPPIV enzymatic activity seems to be 
required for neutrophil chemorepulsion. In addition to DPPIV directly regulating 
neutrophil chemorepulsion, DPPIV could cleave a component of the media, such as 
creating a breakdown component of BSA that acts as a chemorepellent. To determine 
whether a component of the media was broken down by rDPPIV, BSA-RPMI or human 
albumin-RPMI were incubated with rDPPIV for 3 hours. While BSA is not pure, the 
human albumin media appears to contain only human albumin and DPPIV as protein 
components (Figure 10A and 10B). In both cases, there was no indication of cleavage 
products accumulating over time, or when time points are compared in the presence and 
absence of rDPPIV (Figure 10A and 10B).  
 
Purified neutrophils are chemorepulsed by DPPIV  
A protein or peptide released by contaminating cells into the media and then 
cleaved by DPPIV could also act as the chemorepellent. Neutrophils were further 
purified after isolation, resuspended in pure human albumin, and assayed for 
chemorepulsion from DPPIV. Both the number of contaminating eosinophils and 
monocytes in the neutrophil preparation decreased significantly following depletion 
(Figure 10C). Neutrophils were 97% pure following CD244 depletion, making a gradient 
of attractant or repellent from remaining contaminating cells unlikely (Figure 10C). Pure 
neutrophils showed a biased movement away from rDPPIV (Figure 10D). These data 
 54 
 
suggest that it is unlikely that DPPIV cleaves a component of the media or from 
contaminating cells to induce chemorepulsion.  
 
 
 
 
Figure 10: Purified neutrophils are chemorepulsed by DPPIV. A) 2% BSA-RPMI or B) 2% 
human albumin-RPMI was incubated with (+) or without (-) 300 ng/ml rDPPIV for 3 hours. 
Time at which samples were taken is given in minutes. Gels were silver stained to identify 
cleavage products. Molecular masses in kDa are indicated at left, and * indicates the position of 
DPPIV and the arrow indicates the position of albumin. C) Isolated neutrophils were further 
purified by CD244 depletion. Purity was determined by morphology. Values are mean ± SEM. n 
= 7. ** and *** indicate that percentages after depletion are statistically different from their 
paired before percentage with p < 0.01 and p < 0.001, respectively (t-test). PMN indicates 
neutrophils, Eos indicates eosinophils, Mono indicates monocytes, and Lympho indicates 
lymphocytes. D) The forward migration index is shown for a DPPIV gradient on purified 
neutrophils in 2% human albumin-RPMI buffer. Values are mean ± SEM. n = 7. ** indicates 
values are statistically significant from the control with p < 0.01 (two-tailed unpaired t-test).  
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Figure 11: The effect of neutrophil conditioned media on chemorepulsion. A) The forward 
migration index is shown for gradients of conditioned media from DPPIV-treated neutrophils 
(DPPIV CM), gradients of this material treated with DPPIV inhibitor, and gradients of 
conditioned media from buffer-treated neutrophils (Buffer CM). Values are mean ± SEM. n = 4. 
* and ** indicate values are statistically significant from the control with p < 0.05 and p < 0.01, 
respectively (two-tailed unpaired t-test). B) A western blot of conditioned media using anti-
DPPIV antibodies. The position of molecular mass standards (in kDa) is indicated on the left. 
 
 
 
Conditioned medium from neutrophils does not affect chemorepulsion 
 Proteases on the neutrophil surface could create a neutrophil chemorepellent or 
cleave a breakdown component of the media that acts as a chemorepellent. Additionally, 
neutrophils could be releasing a chemorepellent or chemoattractant that is then affected 
by DPPIV. To determine if neutrophil proteins are responsible for the chemorepulsion 
effect, neutrophils were incubated with DPPIV or an equivalent volume of buffer for 30 
minutes at 37°C. Neutrophils were then collected by centrifugation, the conditioned 
media recovered, and media from the outer chamber of the Insall chamber was replaced 
with this conditioned media. Half of the conditioned media from cells pre-incubated with 
DPPIV was mixed with the DPPIV inhibitor DPPIV 1c hydrochloride immediately 
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before addition to the Insall chamber. Conditioned media from buffer-treated cells or 
conditioned media from DPPIV-treated cells that was mixed with the inhibitor failed to 
promote chemorepulsion of neutrophils (Figure 11A). Conditioned media from DPPIV-
treated cells did promote chemorepulsion of neutrophils (Figure 11A). As determined by 
Western blots stained with anti-DPPIV antibodies, there was no detectable DPPIV 
present in conditioned media from buffer-treated cells, while there was DPPIV present in 
the conditioned media from DPPIV-treated cells (Figure 11B). Together, these data 
suggest that DPPIV promotes neutrophil chemorepulsion, rather than cleaving a 
component of the media or a substrate secreted from cells. 
 
DPPIV reduces the number of neutrophils in lungs of mice treated with bleomycin 
 Oropharyngeal aspiration of bleomycin in mice causes neutrophils to accumulate 
in the lungs within 24 hours of bleomycin administration (170). If DPPIV functions as a 
neutrophil chemorepellent, then administering DPPIV to a tissue could drive neutrophils 
out of the tissue or prevent their entry. We examined the ability of DPPIV to affect 
neutrophil accumulation in the lungs of bleomycin-treated mice. Assuming the volume 
of liquid in the airways of mouse lungs is no more than 0.1 ml, administering 0.9 µg of 
DPPIV creates a DPPIV concentration considerably greater than the DPPIV serum 
concentration of 0.4 µg/ml (89). Mice were treated with bleomycin on day 0 and were 
treated with aspirated rDPPIV or an equivalent volume of saline on day 1. Bleomycin is 
metabolized and excreted within 24 hours, so the DPPIV treatment at 24 hours does not 
block the effect of bleomycin (171, 172). Three days after bleomycin treatment, mice 
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were euthanized and weakly adhered cells from the airways were collected by 
bronchoalveolar lavage (BAL). Although the BAL from DPPIV-treated mice appeared 
to have fewer total number of cells than mice given bleomycin alone, this difference was 
not significant (Figure 12A). BALs from mice given rDPPIV following saline had 
significantly less cells than mice given saline or bleomycin alone (Figure 12A). Cell 
morphology was used to determine the total number of neutrophils, macrophages, and 
lymphocytes in the BAL. Significantly fewer neutrophils were present in the BALs from 
bleomycin plus rDPPIV and saline plus rDPPIV treated mice compared to mice treated 
with bleomycin alone (Figure 12B). There was no difference in total macrophage or 
lymphocyte numbers in the BAL between DPPIV-treated mice and their untreated 
counterparts (Figure 12B). Following BAL, lungs were sectioned and stained with anti-
mouse Ly6G to detect neutrophils. There were significantly fewer Ly6G positive cells in 
the post-BAL lungs of mice treated with bleomycin and then treated with DPPIV on day 
1 than the post-BAL lungs of mice treated with bleomycin alone (Figure 12C and 12D). 
There was no difference in the numbers of CD11b, CD11c, CD206, or CD107b (Mac3) 
positive cells in the lungs of mice treated with bleomycin compared to those treated with 
bleomycin and then treated with DPPIV (Figure 12E), suggesting that the effect of 
DPPIV is specific to neutrophils. 
DPPIV regulates GLP-1, which regulates glucose levels in the blood (173). 
Inhibiting DPPIV affects glucose levels in mice (174). To determine if oropharyngeal 
aspiration of DPPIV at day 1 affected weight gain or serum glucose levels, we measured 
weight change over 3 days and measured glucose levels in the blood of mice euthanized 
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Figure 12: DPPIV reduces the number of neutrophils in bleomycin-treated lungs. Mice were treated with 3 U/kg 
bleomycin by oropharyngeal aspiration on day 0. On day 1, mice were treated with oropharyngeal aspiration of 0.9 µg 
of human rDPPIV or an equal volume of buffer. Mice were sacrificed on day 3 and cells were collected by BAL. A) 
The total number of cells collected from the BAL. Values are mean ± SEM (n = 4 bleomycin and bleomycin + DPPIV, 
n = 3 saline and saline + DPPIV). B) The total number of neutrophils, macrophages, and lymphocytes obtained in the 
BAL for the above experimental groups. Values are mean ± SEM (n = 4 bleomycin and bleomycin + DPPIV, n = 3 
saline and saline + DPPIV). * and ** indicate a significant difference with p < 0.05 or p < 0.01, respectively, as 
determined by paired one-tailed t-tests. C) Lung sections were stained with anti-mouse Ly6G to detect neutrophils. 
Arrows indicate Ly6G positive cells. Scale bars are 50 µm. D) Counts of Ly6G positive cells in lung sections. Values 
are mean ± SEM (n = 4 for bleomycin and bleomycin + DPPIV, n = 3 for saline and saline + DPPIV). * indicates a 
significant difference with p < 0.05 as determined by paired two-tailed t-test. E) Counts of CD11b, CD11c, CD206, or 
CD107b (Mac3) positive cells in lun. sections. Values are mean ± SEM (n = 3). * and ** indicate a significant 
difference with p < 0.05 or p < 0.01, respectively, as determined by paired two-tailed t-test. 
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Figure 13:  Physiological responses of mice treated with DPPIV. Mice were treated with 3 U/kg 
bleomycin by oropharyngeal aspiration on day 0. On day 1, mice were treated with 
oropharyngeal aspiration of 0.9 µg of human rDPPIV or an equal volume of buffer. Mice were 
sacrificed on day 3. Values are mean ± SEM (n = 4 bleomycin and bleomycin + DPPIV, n = 3 
saline and saline + DPPIV). A) DPPIV reduces the weight loss caused by bleomycin 
administration and has no effect on weight gain in control mice. B) DPPIV has no effect on 
blood glucose levels.  
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 on day 3. Although not statistically significant, DPPIV administration appeared 
to rescue the weight loss caused by bleomycin and had no significant impact on weight 
gain when administered on day 1 to mice given saline on day 0 (Figure 13A). 
Additionally, DPPIV administration had no significant effect on serum glucose levels at 
day 3 (Figure 13B). Together, our results indicate that DPPIV reduces the accumulation 
of neutrophils in the lungs of mice but does not cause significant changes in weight or 
serum glucose levels two days after administration.  
 
 
DPPIV does not promote or inhibit neutrophil survival 
The number of cells in any tissue is dependent on four factors; proliferation, death, 
recruitment, and emigration (175). As neutrophils are terminally differentiated cells, 
proliferation is not likely to regulate neutrophil numbers in an inflammatory 
environment. To determine if the reduction in the number of neutrophils in DPPIV-
treated lungs was due to altered cell survival, we cultured human neutrophils in the 
presence or absence of DPPIV for 20 hours. In the absence of exogenous proteins, the 
majority of neutrophils were apoptotic, as determined by Annexin V staining and 
morphological changes (Figure 14A and 14B). The addition of DPPIV had no significant 
effect on neutrophil survival (Figure 14A-C). To determine if DPPIV was regulating 
neutrophil survival in vivo, we stained lung sections with antibodies against active 
caspase-3. Similar to previous observations in the presence or absence of bleomycin, 
there was no difference in the number of cells labeled with active caspase-3 antibodies 
with the addition of DPPIV (Figure 14D) (176). These data indicate that the reduction in  
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Figure 14: DPPIV does not regulate neutrophil survival. Human neutrophils were incubated for 20 
hours in the presence or absence of TNF-a, IL-8, or DPPIV. Values are mean ± SEM. A) 
Neutrophils were identified by their forward and side scatter characteristics and the number of 
propidium iodide negative cells were counted by flow cytometry. n=4. B) The percentage of 
Annexin V positive neutrophils was determined by flow cytometry. n=3. C) The percentage of 
apoptotic neutrophils was assessed by counting nuclei with apoptotic morphology on cytospin 
preparations. n=3. D) Counts of activated caspase-3 in lung sections. n=3. 
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the number of neutrophils in the lungs of mice following DPPIV administration is 
unlikely to be due to increased neutrophil cell death. 
 
Discussion  
 We previously characterized AprA as an endogenous chemorepellent of 
Dictyostelium cells (48). Here, we identified structural similarities between AprA and 
human DPPIV, and found that DPPIV appears to act as a neutrophil chemorepellent at 
physiological concentrations.  
In the Insall chambers, we observed a strong DPPIV chemorepellent effect using 
a 0 to 100 ng/ml (0-1.2 nM) gradient. The gradient in the Insall chamber forms over a 
970-µm gap. Making the first-order assumption that the gradient is linear, DPPIV is 
effective at 0.10 ng/ml/µm, or 0.0012 nM/µm. With an observed average neutrophil 
length of 10.5 µm (consistent with previous observations) (177), a cell in the middle of 
the gradient would correspond to a difference of 1.1 ng over the length of the cell at a 
place where the average DPPIV concentration is 50 ng/ml. This would then represent a 
2.2% difference in the DPPIV concentration between the front and the back of the cell. 
For the 4.7-11.7 nM and the 9.4-23 nM gradients, the difference is 0.9%. This is similar 
to the 1.25% concentration difference of cAMP that induces chemotaxis for aggregating 
Dictyostelium cells (164), or the 1% fMLP concentration gradient that induces 
neutrophil chemotaxis (178).  
 For unknown reasons, we observed that for all of the DPPIV gradients in the 
Insall chambers, approximately 17% of the neutrophils showed movement toward the 
 63 
 
source of DPPIV over 10 minutes. There was no obvious difference in the percentage of 
cells moving toward DPPIV as a function of the DPPIV concentration gradient. This 
effect is strikingly similar to the observation that 17% of Dictyostelium cells also move 
toward a source of AprA in the Insall chambers (48). At the lowest gradient 
concentration used, the DPPIV concentration at the middle of the gradient was 0.6 nM, 
or ~110 DPPIV molecules per cell volume in the extracellular environment. By Poisson 
statistics, there could be momentary conditions where the cell does not detect the 
gradient or detects an ‘opposite’ gradient. However, over 10 minutes all cells should 
detect the gradient. As the percentage of non-neutrophils in both isolated and purified 
neutrophils is below 17% of the total population, some portion of the backwards moving 
cells must be neutrophils. The existence of cells moving backwards thus indicates an 
unknown heterogeneity in both Dictyostelium cells and human neutrophils.   
Inhibitors that block the active site of DPPIV also blocked the ability of DPPIV 
to act as a chemorepellent. It is possible that the inhibitors disrupt the DPPIV structure, 
and therefore disturb its ability to act as a ligand for a chemorepellent receptor. 
However, the crystal structure of human DPPIV in a complex with Diprotin A shows no 
significant structural difference compared to DPPIV alone (179). This suggests that the 
inhibitors block chemorepulsion in some other manner, such as blocking the ability to 
cleave something in the assay medium. In the Insall chamber assays, neutrophils were in 
RPMI containing BSA or human albumin, on a fibronectin surface. The only known 
enzymatic activity of DPPIV is cleavage of two amino acids from the N-terminus of a 
protein if the second amino acid is a proline or alanine (81). RPMI does not contain 
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proteins, and BSA and human albumin do not have a proline or an alanine as the second 
amino acid. Additionally, no cleavage products of BSA or human albumin were seen 
following incubation with rDPPIV for 3 hours. DPPIV does not cleave fibronectin (180). 
Following CD244 depletion, neutrophils were 97% pure and rDPPIV was still able to 
cause repulsion, indicating that a factor secreted by cells contaminating the neutrophil 
preparation is not likely responsible for the effect. There are no known neutrophil-
secreted neutrophil chemoattractants that are, or could be, affected by DPPIV (146, 181-
185). Conditioned media from neutrophils incubated with buffer alone did not cause 
attraction or repulsion of neutrophils, supporting this idea. Conditioned media from 
neutrophils incubated with DPPIV caused chemorepulsion of neutrophils. The 
chemorepulsive activity of the conditioned media was lost with the addition of a DPPIV 
inhibitor, suggesting the chemorepulsive activity in the conditioned media is due 
specifically to the presence of DPPIV activity. Although DPPIV-induced neutrophil 
chemorepulsion appears to require the DPPIV active site, the chemorepulsion does not 
appear to be caused by DPPIV’s enzymatic activity on material in the medium, on 
chemoattractants or repellents, or components from cells.  
DPPIV knockout mice have been generated (89) and rat strains lacking DPPIV 
have been identified (90, 91). DPPIV deficient animals have normal blood levels of most 
leukocytes, including neutrophils (92-94). Arthritic joints in mammals contain 
abnormally high numbers of neutrophils (70). DPPIV knockout mice have increased 
severity of experimentally induced arthritis, with a 2.4 fold increase in the number of 
cells in the joint (95). A two-fold increase in neutrophils occurs in ovalbumin-induced 
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lung inflammation in DPPIV deficient rats compared to normal rats (96). Reduced levels 
of DPPIV correlate with increased inflammation in the joints of rheumatoid arthritis 
patients (97). The increased inflammation observed in DPPIV deficient situations has 
been assumed to be due to a persistent chemokine presence, as DPPIV was not present to 
cleave those chemokines that have an alanine or proline as the second amino acid (98).  
We found that oropharyngeal aspiration of DPPIV caused a reduction in the 
accumulation of neutrophils, but not other immune cells, in the lungs of mice treated 
with bleomycin, suggesting that the chemorepulsive effect of DPPIV is specific to 
neutrophils. In addition, the reduction in neutrophils was not due to increased neutrophil 
death. Our data suggests an alternative hypothesis to the persistence of chemokines in a 
tissue. We hypothesize that DPPIV acts directly as a neutrophil chemorepellent. 
Following neutrophil influx, activated T cells enter a site of inflammation (186). 
Activated T cells highly express membrane DPPIV, and extracellular DPPIV is thought 
to be cleaved from the membrane of T cells (75). An increase in extracellular DPPIV 
could promote neutrophil egress from the inflammatory site. In the resolution of 
zebrafish wounds, neutrophils are able to move out of the tissue and back into the 
vasculature (71). An intriguing possibility is that T cell-released DPPIV may help cause 
the egress of neutrophils out of the lung tissue to resolve lung inflammation. Some lung 
diseases such as acute respiratory distress syndrome (ARDS) involve an excess number 
of neutrophils in the lungs (103). The ability of DPPIV to induce neutrophil 
chemorepulsion suggests the existence of new mechanisms that may be used to treat 
these diseases.  
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CHAPTER IV 
CONCLUSIONS AND FUTRE DIRECTIONS 
 
Conclusions 
Cancer results in half a million deaths per year in the United States, but most 
deaths occur after removal of the primary tumor when metastases proliferate rapidly (2-
7). This suggests a factor is secreted by the primary tumor to keep metastatic cells 
dormant. The 40% mortality rate in ARDS is attributable to an influx of neutrophils that 
further damages lung tissue (100-102, 104, 105). Currently, the specific factors that 
inhibit proliferation of tumor metastases and those that could prevent or slow the influx 
of neutrophils are unknown. In in the model organism, Dictyostelium, we have found a 
factor named AprA that shows promise as a research target for two separate human 
diseases, cancer and ARDS. This dissertation explored the mechanism of proliferation 
inhibition in Dictyostelium discoideum through AprA. AprA’s dual role as a 
chemorepellent allowed us to also analyze the mechanisms of chemorepulsion in 
Dictyostelium cells and neutrophils.  
 The existence of chalones, or factors that inhibit the proliferation of a subset of 
cells, has long been known. Examples such as liver regrowth and tumor dormancy leave 
us questioning the identity of the chalones. Members of the TGF-β superfamily, such as 
myostatin, have been identified as protein chalones. Knowing the identity of the chalone 
leads us to ask what are the mechanisms of proliferation inhibition. In this dissertation, I 
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have used the known Dictyostelium chalone, AprA, to study the mechanism of its 
inhibition.  
 Cellular proliferation is initiated by mitogens that activate downstream signaling. 
Chalones inhibit the proliferation of cells, but it is unclear if they use a reverse of the 
proliferation pathway or function in novel mechanisms to inhibit cellular proliferation. 
We found that the Dictyostelium chalone AprA functions through the PTEN-like protein 
CnrN. PTEN proteins inhibit cellular proliferation and are typically negative regulators 
of proliferation-inducing signaling pathways (113, 125-128). Activating a PTEN would 
block any proliferation-promoting signals by counteracting the PI3K pathway (113, 125-
128). Previous work found that AprA requires a ROCO kinase, a basic leucine zipper 
transcription factor, and a retinoblastoma tumor suppressor to inhibit Dictyostelium cell 
proliferation (45-47). The work in this dissertation combined with previous work 
suggests that chalones may function in two ways (1) to block proliferation-promoting 
pathways and (2) to activate their own set of transcription factors to induce genes to 
inhibit proliferation. This could identify new methods to inhibit the proliferation of cells 
such as in cancer. The work in this dissertation suggests that a better way to mediate cell 
division may be to activate suppressor pathways rather than block proliferative 
pathways. Activating PTENs to ‘naturally’ inhibit proliferation pathways may be more 
beneficial than blocking the signals in the proliferation pathway. This work could also 
identify ways to block the inhibition of proliferation when regrowth is necessary. The 
regulation of tissue sizes suggests that progenitor cell division, such as the case with 
myoblasts, are highly regulated (10). It is tempting to speculate that enhancing 
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progenitor cell division could be used for therapies such as rapid muscle recovery 
following surgical atrophy or improve blood cell counts following chemotherapy. The 
dissertation work suggests that cell proliferation is inhibited by activating suppressors of 
proliferation. Therapies could be developed to reversibly inactivate proliferation 
inhibitors to allow regrowth when necessary.  
 ARDS results in 40% mortality and currently has no effective treatment (100-
102, 104). Lung tissue damage in ARDS patients is attenuated by the release of 
proteases and reactive oxygen species from infiltrated neutrophils (104, 105). Other 
diseases, such as rheumatoid arthritis (RA), are characterized by neutrophil-induced 
damage (70). A need exists for a mechanism to stop neutrophil damage in these diseases 
so resolution and repair can occur.  
 Reverse migration, or movement of cells out of a tissue back into the 
bloodstream, would serve to remove neutrophils from a damaged environment and allow 
resolution to begin. Recently, reverse migration has been observed in vivo in zebrafish 
and both in vitro and in vivo in mice (71, 73). Chemorepellents are molecules that cause 
cell movement away from the substance. One could induce reverse migration of cells 
through application of a chemorepellent. A number of chemorepellents including those 
for Dictyostelium, neurons, mast cells, neutrophils, and cancer cells have been identified 
(49, 63-66).  
 In this dissertation, a novel neutrophil chemorepellent, DPPIV, was identified 
based on its structural similarity to the Dictyostelium chemorepellent, AprA (187). A 
number of studies have shown that structural similarities equate to functional similarities 
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(139-144). We examined whether DPPIV, like AprA, had chemorepellent activity. We 
found that in vitro a gradient of DPPIV could chemorepulse human neutrophils above, 
below, and within physiological concentrations. Cleavage of substrates by DPPIV 
enzymatic activity is known to effect chemotaxis (77, 81, 99). Although we found that 
the enzymatic activity of DPPIV is necessary for chemorepulsion, DPPIV did not cleave 
another substance to induce a secondary gradient of chemorepellent.  
Approximately 17% of cells in any given experiment moved toward the source of 
DPPIV. Intriguingly, 17% of Dictyostelium cells moved toward AprA (187). It would be 
of interest to determine why these subsets of cells respond differently than most. Using 
Dictyostelium, one could use under agarose assays to isolate the chemoattracted cells. 
These cells could be enriched for in culture and analyzed for their varying properties. A 
Boyden chamber assay with DPPIV in the top would isolate chemoattracted or 
unresponsive neutrophils in the top of the well. All chemorepulsed neutrophils would 
migrate through the filter to the bottom well. These neutrophils could be analyzed for 
differences from the neutrophils in the bottom well. One would expect that the cells that 
are chemoattracted and those that are chemorepulsed would display differing 
characteristics. These could easily be identified by examining cell surface markers on 
either Dictyostelium cells or neutrophils. Neutrophil activation status could also be 
determined, observing their ability to adhere to surfaces, produce reactive oxygen 
species, and chemotax.   
 Diseases such as ARDS and RA have a misregulation in neutrophil clearance 
from the injured tissue (70, 102, 103, 107). We examined the ability of DPPIV to repulse 
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neutrophils from the lungs of a mouse model of ARDS. DPPIV did not affect the 
number of CD11b, CD11c, CD206, or Mac3 positive cells. DPPIV specifically acted to 
reduce the accumulation of neutrophils in the lungs of these mice. This was true for 
neutrophils within the air space and those in the alveolar tissue. Additionally, DPPIV 
reduced the accumulation of neutrophils in uninjured mice treated with DPPIV. After 
neutrophils enter a tissue and clear the infection, many undergo apoptosis and are 
ingested by macrophages (188). One reason DPPIV could reduce the accumulation of 
neutrophils in a tissue is by promoting apoptosis. DPPIV did not inhibit or promote 
apoptosis in vitro with human neutrophils or in vivo on mouse neutrophils in the lungs. 
This leaves two mechanisms for the reduction of neutrophils in the lungs to be studied in 
future work. DPPIV may either block the movement of neutrophils into the lungs or 
promote their reverse migration out of the lungs.  
 Both tumor dormancy and ARDS are diseases with high mortalities and few 
effective non-toxic treatments. This dissertation approaches these diseases through the 
unique link in the model organism Dictyostelium. A secreted protein, AprA, in 
Dictyostelium acts as an inhibitor of proliferation and a chemorepellent. A human 
structural equivalent of AprA, called DPPIV functions as a chemorepellent of human 
and mouse neutrophils. Future work will help expand the knowledge about the 
mechanisms of chalone and chemorepellent signaling, with an ultimate goal in 
identifying novel candidates for therapies of tumor dormancy and ARDS.   
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Future Work  
 There are a number of ways the work in this dissertation can be further 
developed. Several ways are outlined in the following section.  
 Identify other components of the AprA chalone and chemorepulsion pathways. 
Use restriction-enzyme mediated insertion (REMI) screens in Dictyostelium to 
identify new mutants or screen known mutants by their ability to respond to 
AprA in proliferation inhibition and chemorepulsion assays.  
 Are AprA and CfaD conserved enough in structure to act on cancer cells? Add 
rAprA, rCfaD, or a combination on to various cancer lines and determine if 
proliferation is inhibited in any of the cancer lines.  
 We determined that CnrN is necessary for chemorepulsion by AprA and that 
AprA can induce CnrN to localize to the membrane. Can CnrN affect the ability 
of cells to polarize? The localization of CnrN in polarized cells could be 
determined and mutant lines could be examined for polarization along with work 
suggested in the next bullet.  
 Determine the mechanism and components that are necessary for 
chemorepulsion. Many GFP lines of Dictyostelium are available through the 
Dicty Stock Center (http://dictybase.org/StockCenter/StockCenter.html). Utilize 
these and/or use conjugated antibodies to determine if AprA cause polarization of 
Dictyostelium cells. Additionally, live cell imaging could be used with the GFP 
lines to determine a time course for AprA signaling. Likewise, conjugated 
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antibodies could be used to identify if DPPIV polarizes neutrophils and a time 
course for neutrophil signaling may be done using markers and flow cytometry. 
 Examine the effect of DPPIV on neutrophil activation. Besides chemotaxing, 
does DPPIV affect cell adhesion, induction of ROS production, or changes in 
surface expression (degranulation)?  
 Further investigate the role of enzymatic activity of DPPIV. Create mutants that 
lack enzymatic activity, but do not affect binding properties. Investigate if these 
mutants have the same or abolished ability to cause chemorepulsion.  
 Explore the mechanisms DPPIV uses in mouse models of ARDS.  
o Use a time course after DPPIV treatment to determine whether DPPIV 
prevents neutrophil influx or promotes their egress after an initial influx. 
If we find a time point where neutrophils are moving out of the lung, use 
intravital microscopy to visualize the cells moving between the tissue and 
blood.  
o Several groups have shown that reverse migrated neutrophils have 
different expression patterns. Examine neutrophils in mice 3 days after 
DPPIV treatment (or at a time from time course experiment) to determine 
if any neutrophils have reverse migrated into the blood.  
o We have shown that collected nebulized rDPPIV (nebulizing DPPIV, 
collecting it in a tube, and testing this on cells) can act as a 
chemorepellent in vitro on human neutrophils and works through 
oropharyngeal aspiration in mice. Investigate whether ARDS mice 
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allowed to freely breathe nebulized rDPPIV have a reduction in 
neutrophils in the lungs. This would mimic the route to be used for 
human treatment.  
 Examine blood from healthy subjects, patients with ARDS, and patients who 
have recovered from ARDS for the presence of reverse migrated neutrophils.  
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APPENDIX A 
STRUCTURAL SIMILARITIES BETWEEN THE DICTYOSTELIUM PROTEIN 
APRA AND THE HUMAN PROTEIN DIPEPTIDYL-PEPTIDASE IV INFER 
FUNCTIONAL SIMILARITIES 
 
Summary 
While sequence similarity often signifies similar function, proteins with 
structural similarities may also indicate convergent function. We were working with the 
Dictyostelium secreted protein, AprA, which had no sequence similarity to any human 
proteins. We found that a predicted structure of AprA had structural similarity to the 
human protein dipeptidyl peptidase IV (DPPIV). Additionally, we found that both AprA 
and DPPIV were able to function as chemorepellents of cells. This led us to investigate 
the idea that structural similarities, like sequence similarities, could equate to functional 
similarities. The work in this appendix takes the functional attributes of one protein and 
examines if the protein structure similarity allows for similar functional properties in the 
other. For example, can the ability of AprA to inhibit the proliferation of cells translate 
into DPPIV being able to inhibit the proliferation of cells? We found that AprA and 
DPPIV share many of the same functional properties.  
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Introduction 
AprA is a secreted Dictyostelium protein that both inhibits the proliferation and 
causes chemorepulsion of Dictyostelium cells (39, 48). AprA functions in conjunction 
with another secreted protein called CfaD, which also inhibits the proliferation of 
Dictyostelium cells (40). Loss of the AprA or CfaD proteins results in cells that 
proliferate faster and reach a higher density than wild type cells (39, 40). The addition of 
recombinant AprA (rAprA) or CfaD (rCfaD) to wild type cells causes a significant 
reduction in cell proliferation (40, 41). rAprA reduces the proliferation of aprA¯ cells, 
but not cfaD¯  cells (41). Likewise, rCfaD can inhibit the proliferation of cfaD¯  cells, 
but not aprA¯ cells indicating the two proteins are necessary for each other’s function 
(40). In addition to its ability to inhibit Dictyostelium cell proliferation, AprA 
chemorepulses Dictyostelium cells (48). Cells at the edge of wild type colonies move 
away from the dense colony center while cells at the edge of an aprA¯ colony form a 
tight edge with little movement outward (46). Additionally, both wild type and aprA¯ 
cells move away from a source of rAprA (48).  
DPPIV is a 110 kDa protein that can be found in a transmembrane or soluble 
form (145). The membrane form is found on some lymphocytes and epithelial cells and 
has a number of binding partners including adenosine deaminase, fibronectin, and 
collagen (75, 76, 86, 87). Additionally, the cytoplasmic portion of the membrane form 
can bind CD45 (87). The heavily glycosylated form is found in most bodily fluids (75, 
76). Both the membrane and soluble forms have serine protease activity. They cleave 
proteins or peptides with a proline or alanine at the second position of the N-terminus 
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(145). One of the major functions of DPPIV is the cleavage of glucagon-like peptide-1 
(GLP-1), which normally increases the secretion of insulin to promote glucose uptake 
(83). DPPIV cleavage of GLP-1 inhibits this process. Inhibitors of DPPIV are used as 
treatment for type 2 diabetes (83). 
Protein structure prediction can reveal protein function that was not obvious from 
sequence analysis. Structure prediction can be extremely accurate (139-144). Structure 
based classification can help identify related proteins that have low sequence similarities 
(189, 190). Lectins, which bind carbohydrates, contain a characteristic structural fold 
(190). Although the fold is present in many different protein families with proteins that 
bind carbohydrates, there is little or no sequence similarity within the fold (190). Heat 
shock proteins and α-crystallins share a common structure of anti-parallel β-strands 
where distinct sequence similarity is not present (191). These studies are evidence that 
structural and functional properties may be comparable even when sequence similarities 
are lacking.   
The AprA protein has no amino acid sequence similarity to human proteins. 
Previously we found that the predicted structure of AprA has structural similarity to the 
crystal structure of DPPIV (187). AprA chemorepulses Dictyostelium cells, and as 
Dictyostelium cells paved the way for neutrophil chemotaxis, we found that DPPIV can 
chemorepulse human and mouse neutrophils (48, 187). In this report, we sought to 
identify other functional similarities between AprA and DPPIV. We show that besides 
their ability to chemorepulse cells, AprA and DPPIV have a number of functional 
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similarities. This suggests that protein structure similarity may be a good predictor of 
protein function where sequence similarities are absent.  
 
Methods  
 Wild-type, aprA−, and cfaD− cells were grown as previously described (192). 
Proliferation inhibition  and chemorepulsion assays were done as previously described 
(132). rDPPIV (Enzo) was used at 300 ng/ml or at various concentrations in proliferation 
inhibition assays. An equivalent volume of buffer (10 mM Tris, 100 mM NaCl) was 
used as a control. For rAprA binding, 10% serum or 100 µg/ml of collagen I, Collagen 
IV, plasma fibronectin, cellular fibronectin, fibronectin 110, fibronectin 45, or adenosine 
demainase was added to appropriate wells and incubated overnight at 4°C. Wells were 
washed with PBST and blocked with 4% BSA/PBS. Positive wells were labeled with 10 
µg/ml rAprA. rAprA was detected with rabbit anti-AprA antibodies (Bethyl 
Laboratories) and read with Synergy Mx (BioTek). Conditioned media from log phase 
cells was collected as previously described (132). DPPIV-like enzymatic activity of 
conditioned media was measured using various concentrations of pNA substrate (H-Gly-
Pro-pNA · p-tosylate) for 60 minutes at room temperature and read at 410nm. Prism 
(Graphpad Software) was used to perform all statistical analyses.  
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Results 
Like AprA, DPPIV can inhibit the proliferation of Dictyostelium cells 
rAprA inhibits the proliferation of wild type Dictyostelium cells (41). To 
determine if rDPPIV functions similarly to rAprA and inhibits the proliferation of 
Dictyostelium cells, 300 ng/ml rDPPIV was added to wild type cells. rDPPIV inhibits the 
proliferation of wild type cells (Figure 15A). Various concentrations of rDPPIV were 
added to wild type cells and rDPPIV was able to inhibit cellular proliferation of wild 
type cells within a certain concentration range (Figure 15B). rDPPIV was unable to 
inhibit the proliferation of Dictyostelium cells at 0.3 ng/ml as indicated by a statistical 
difference compared to rAprA inhibition from Figure 15A (Figure 15B). To determine if 
rDPPIV could function to inhibit proliferation in the absence of endogenous AprA or its 
counterpart CfaD, rDPPIV was added to AprA or CfaD mutant cells. rDPPIV was able 
to inhibit the proliferation of aprA¯ and cfaD¯ cells in the absence of these endogenous 
proteins (Figure 16). Together, these data indicate that DPPIV can function similarly to 
AprA by inhibiting the proliferation of Dictyostelium cells. Moreover, DPPIV does not 
require the endogenous AprA or CfaD proteins to exert its effect.  
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Figure 15: rDPPIV inhibits proliferation of wild-type Dictyostelium cells. A) rDPPIV, 
rAprA, or rCfaD was added to wild-type cells at 300ng/ml. B) Various concentrations of rDPPIV 
were added to wild-type cells and proliferation counted after 16 hours. The percent of 
proliferation inhibition compared to control cell density is shown. Values are mean ± SEM. * 
indicates p < 0.05 from rAprA percent inhibition from (A). 
 
 
 
Like DPPIV, rAprA can bind fibronectin 
 DPPIV is known to have a number of binding partners including fibronectin, 
adenosine deaminase, and collagen (86). Fibronectin, collagen, adenosine deaminase, or 
10% serum were coated on a plate and the ability of rAprA to bind them was accessed. 
rAprA was able to bind both cellular and plasma fibronectin but not the 110 kDa or 45 
kDa fragments of fibronectin (Figure 17). Additionally, rAprA appears to weakly bind 
collagen although binding is not statistically different from BSA control (Figure 17). 
This indicates that like DPPIV, AprA can bind fibronectin, but not any of the other 
DPPIV-binding partners.  
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Figure 16: rDPPIV inhibits proliferation of aprA¯ and cfaD¯  Dictyostelium cells. 
rDPPIV was added to cells at 300ng/ml and proliferation counted after 16 hours. The percent of 
proliferation inhibition compared to control cells is shown. Values are mean ± SEM, n=3.  
 
 
Figure 17: rAprA binds fibronectin, but not collagen, serum proteins, or adenosine 
deaminase. Plates were coated with bovine serum albumin (BSA), cellular fibronectin (FnC), 
plasma fibronectin (FnP), the 110 –kDa fibronectin fragment (Fn110), the 45-kDa fibronectin 
fragment (Fn45), collagen I, collagen IV, 10% serum, or adenosine deaminase and anti-AprA 
was used to determine if rAprA bound the substances. Values are mean ± SEM, n=3. **, p < 
0.01; ***, p < 0.001 (one-way ANOVA). 
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Dictyostelium conditioned media has DPPIV-like enzymatic activity 
 DPPIV has serine protease activity, cleaving peptides or proteins with a proline 
or alanine in the second position at the N-terminus (77, 167). Conditioned media was 
collected from log-phase wild type or aprA¯ cells and tested for its ability to cleave the 
substrate H-Gly-Pro-pNA p-tosylate. Wild type conditioned media had statistically 
significantly more DPPIV-like enzymatic activity than conditioned media from cells 
lacking AprA (Figure 18). This suggests that AprA in the conditioned media may be 
responsible for the DPPIV-like activity.  
 
 
 
 
 
Figure 18: Dictyostelium conditioned media (CM) lacking AprA has reduced DPPIV-like 
enzyme activity. Wild-type or aprA¯ CM was incubated with various concentrations of H-Gly-
Pro-pNA p-tosylate. Values are mean ± SEM, n=3. * indicates p < 0.05.  
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Like AprA, rDPPIV can chemorepulse Dictyostelium cells 
 In addition to its ability to inhibit proliferation, AprA causes chemorepulsion of 
Dictyostelium cells (48). Buffer solutions of recombinant AprA, recombinant DPPIV, or 
buffer alone were analyzed for their ability to cause chemorepulsion of wild type cells. 
DPPIV can also chemorepulse Dictyostelium cells with a similar strength to AprA 
(Figure 19). These data indicate that AprA and DPPIV both possess the ability to 
chemorepulse Dictyostelium cells.  
 
 
 
 
 
Figure 19: rDPPIV induces chemorepulsion of Dictyostelium cells. 2000 ng/ml of rDPPIV or 
rAprA was added to one side of an Insall chamber. Movement of cells was observed by videomicroscopy 
and displacement on the x-axis was plotted in microns.  Values are mean ± SEM, n=3. ** and *** indicate 
statistical significance from buffer with p <0.01 and p < 0.001, respectively. 
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Discussion 
 A number of recent studies suggest that using protein structure to predict or 
identify protein function is accurate and may be better than using protein sequences 
(139-144). The Dictyostelium protein AprA and the human protein DPPIV share 
structural similarity, but lack much sequence similarity. Here we show that AprA and 
DPPIV also have functional similarity. Like AprA, DPPIV is able to inhibit the 
proliferation and chemorepulse Dictyostelium cells. Like DPPIV, AprA can bind 
fibronectin and weakly to collagen. Additionally, AprA may be responsible for DPPIV-
like enzymatic activity in Dictyostelium conditioned media. It is clear from this work 
that structural similarity can be used to determine functional similarities in cases where 
sequence similarity is lacking. Although AprA and DPPIV do not share sequence 
similarity, they display a number of functional similarities and DPPIV can even 
substitute for AprA on Dictyostelium cells. Future work will determine if AprA can 
substitute for DPPIV in the chemorepulsion of human neutrophils.  
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APPENDIX B 
THE DICTYOSTELIUM CHALONE CFAD REQUIRES G PROTEINS TO 
INHIBIT PROLIFERATION 
Summary 
 The Dictyostelium chalone AprA signals through the G protein, Gα8. CfaD is a 
second Dictyostelium chalone. AprA and CfaD require each other to function, but may 
activate different signaling effectors. In this part of the dissertation, I sought to identify 
if CfaD also signals with a Gα protein.  
 A previous experiment by Deen Bakthavatsalam found that gα1¯, gα8¯, gα9¯, 
and gβ¯ cells were insensitive to CfaD signals. This indicated that CfaD could signal 
using a G protein. Gα8 and Gα9 have been characterized in previous work by our lab. 
Therefore, this appendix focuses mainly on the properties of Gα1 and CfaD binding to 
Dictyostelium cells.  
 I found that gα1¯ cells proliferate faster than wild type cells and share some, but 
not all of the phenotypes of CfaD mutant cells. Additionally, gα1¯, gα8¯, gα9¯, and gβ¯ 
all appear to be necessary for CfaD to bind to cells. CfaD may signal through Gα1, as 
binding of CfaD is reduced in gα1¯ cells. Together, these data indicate that Gα1 is a 
good candidate for a component of CfaD signaling.  
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Introduction 
The ability to regulate tissue size is an essential process. Tissue size is 
maintained with tight control over cellular proliferation (110). Misregulation in 
proliferation is seen in diseases such as cancer (193). A lack of proliferation control in 
cancer leads to tumor growth, and often death (193). As evidenced from rapid metastatic 
proliferation following primary tumor removal, primary tumors secrete factors to inhibit 
cancer cell proliferation (23-28). Factors that inhibit cell proliferation are termed 
chalones (1, 2).  
Two secreted Dictyostelium chalones have been identified (39, 40). As vegetative 
Dictyostelium populations become dense, these proteins, AprA and CfaD, are enriched 
in the extracellular space (39, 40). AprA and CfaD inhibit proliferation to maintain a 
specific sized population of cells. Cells lacking AprA or CfaD proliferate rapidly (39, 
40). Rapid proliferation is rescued by restoring AprA and CfaD (39, 40). A basic leucine 
zipper transcription factor, a ROCO kinase, and a PTEN-like protein are known 
signaling components in AprA and CfaD proliferation inhibition pathway(s) (45, 46, 
132). Additionally, the Gα protein, Gα8 and a tumor suppressor are necessary for AprA 
signaling (43, 47).  
Gα proteins are part of heterotrimeric complex (194, 195). The G-protein 
complex is composed of Gα, Gβ, and Gγ (194, 195). Typically, G proteins are associated 
with G protein-coupled receptors (194, 195). In its resting state, Gα is associated with 
guanosine diphosphate (GDP) (194, 195). When the receptor is activated, the GDP on 
the Gα is exchanged for guanosine-5’-triphosphate (GTP) (194, 195). Activated Gα is 
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dissociated from Gβγ and both subunits can relay the signal to downstream effectors 
(194, 195). G protein signaling is involved in many signaling cascades including 
proliferation, survival, and chemotaxis (194, 196, 197).  
Here we show that CfaD appears to use the Gα proteins Gα1, Gα8, and Gα9 and 
Gβ to signal Dictyostelium cells to stop proliferating. Additionally, gα1¯ cells have 
proliferation faster than wild type cells and mediate some, but not all of CfaD-induced 
effects. 
 
Methods  
 Wild type, gα1¯, gα8¯, gα9¯, and gβ¯ cells were grown as previously described 
(40). Proliferation, spore viability, mass, protein, and nuclei were done as previously 
described (132). Colony expansion, binding assays, GTPγS was done as previously 
described (43, 46). Statistics were done using Prism Graphpad software.   
 
Results 
gα1¯ cells exhibit a fast proliferation phenotype 
 cfaD¯, gα8¯, gα9¯, and gβ¯ cells have faster proliferation than wild type cells 
(40, 43). gα1¯ cells have faster proliferation (Figure 20A and 20B). gα1¯ cells have a 
significantly faster doubling time than wild type cells (Table 10). Full proliferation 
curves show that although gα1¯ cells proliferate faster than wild type, they do not reach 
a higher maximum cell density (Table 10). gα1¯ cells proliferate at a rate similar to wild 
type cells on bacterial lawns (Figure 20C) and colonies of gα1¯ cells expand more 
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slowly on bacterial lawns than wild type colonies (Figure 20D). This suggests that like 
CfaD, Gα1 may help inhibit cell proliferation.  
 
 
 
 
Figure 20: The effect of Gα1 on proliferation. Values are mean ± SEM, n ≥ 3. Absence of 
error bars indicates error was smaller than the plot symbol. *, **, and *** indicate values with p 
< 0.05, p < 0.01, and p < 0.001, respectively. (A) Cells in shaking culture were started at 1x 105 
cells/ml and counted daily. (B) A Log plot of the first 5 days from A. (C) 1x103 cells were 
plated and counted daily, after 48 hours, WT cells cleared the plate. (D) Cells were plated at low 
density to form individual colonies. At least 3 colony diameters per plate were measured daily. 
After day 8, wild type colonies were indistinguishable from each other.   
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Table 10. The effect of Gα1 on doubling time and stationary density. Doubling times and 
maximum densities were calculated from the data in Figure 20. Values are mean ± SEM, n ≥ 3. 
Values are statistically different from wild type with p < 0.01 (t-test). 
 
Cell Type Doubling time, hours 
Maximum observed 
cell density, 10
6
 cells/ml 
Wild-type 14.9 ± 1.0 24 ± 1 
gα1¯ 9.7 ± 1.3** 26 ± 2 
 
 
 
 
 
 
gα1¯ cells are multinucleate 
Cells lacking CfaD are multinucleate (40). Previous work has shown that 
overexpressing Gα1 leads to a multinucleate phenotype (198, 199). DAPI stained cells 
were counted for their number of nuclei to determine if gα1¯ cells are multinucleate. We 
found that gα1¯ have less with one nucleus and more cells with 3 or more nuclei (Table 
11). Together, these data indicate that loss or gain of Gα1 causes disruption in normal 
nuclei phenotypes.    
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Table 11. The effect of Gα1 on nuclei per cell. DAPI stained cells were counted for the 
presence of 1, 2, or 3 or more nuclei. Values are mean ± SEM (n=4). * and ** indicate p < 0.05 
and p < 0.01, respectively.  
 
 Percent of cells with n nuclei 
Cell Type 1 2 3+ 
Wild-type 60 ± 3 36 ± 4 3 ± 2 
gα1¯ 48 ± 5* 37 ± 4 15 ±1** 
 
 
 
Gα1 has no effect on cell growth 
 Proliferation, an increase in the number of cells, and growth, an increase in the 
mass of a cell, are processes that can be regulated together or independently of each 
other (43, 110). Gα1 regulates cell proliferation. To determine if Gα1 regulates growth, 
mass and protein content were measured. There was no difference in mass content 
compared to wild type cells (Table 12). gα1¯ cells had significantly more protein content 
than wild type cells (Table 12). However, when the protein content was corrected for the 
multinucleate phenotype of gα1¯ cells, there was no difference in protein content.  
 Doubling times were used to calculate the accumulation of mass, protein, and 
nuclei per hour. We would expect an increase in cell number would result in an increase 
of mass, protein, and nuclei. There were no differences in mass or protein accumulation 
between gα1¯ cells and wild type cells (Table 13). gα1¯ cells accumulated more nuclei 
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per hour than wild type cells (Table 13). Together, this data indicates that Gα1 does not 
control cell growth.   
 
 
Table 12. The effect of Gα1 on the mass and protein content of cells. Mass and protein 
content was measured. Data from Table 11 was used to calculate the nuclei per 100 cells. Nuclei 
per 100 cells was used to calculate the mass and protein content per 107 nuclei. * and ** indicate 
values are statistically significant from wild type with p < 0.05 and p < 0.01, respectively. 
Values are mean ± SEM, n ≥ 3.  
 
 
 
 
 
 
Table 13. The effect of Gα1 on mass and protein accumulation of cells. Doubling times from 
Table 10 were used to determine mass, protein, and nuclei accumulation per hour. Mean ± SEM, 
n ≥ 3. Values are statistically significant from wild type at ** with p < 0.01 (t-test). 
 
 Per 107 cells/hour  Per 107 nuclei/hour 
Cell type Mass (µg) Protein (µg) Nuclei, x 10
-5
 Mass (mg) Protein (µg) 
Wild-type 80 ± 12 78 ± 5 6.2 ± 0.2 63 ± 10 65 ± 4 
gα1¯ 111 ± 16 109 ± 15 15.9 ± 2.0** 64 ± 10 63 ± 9 
 
 
 
 Per 107 cells  Per 107 nuclei 
Cell type Mass (mg) Protein (mg) Nuclei/100 cells Mass 
(mg) 
Protein 
(mg) 
Wild-type 12.0 ± 0.05 0.93 ± 0.17 
64.694890 4.365608 5 
 
145 ± 4 8.3 ± 0.4 0.71 ± 0.19 
gα1¯ 12.1 ± 1.1 1.19 ± 0.08* 173 ± 4** 7.0 ± 0.6 0.69 ± 0.05 
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Gα1 is not important for spore development 
 The cost of lacking CfaD is a decrease in the viability of cells (40). gα1¯ cells were 
examined for their ability to develop spores. gα1¯ cells developed a similar number of 
spores to wild type cells (Table 14). Additionally, detergent treated spores from gα1¯ 
cells were as viable as wild type spores (Table 14). This indicates that unlike cfaD¯ 
cells, gα1¯ cells do not have a defect in spore development or viability and that Gα1 
does not play a role in spore sustainability.  
 
Table 14. The effect of Gα1 on spore viability. Cells were developed and spores counted. 
Spores were treated with detergent, plated, and colony formation analyzed to determine viable 
spores. Values are mean ± SEM (n ≥ 3).  
 
 
Cell Type 
Viable spores after 
development as a percent 
of input cell number 
Detergent resistant spores as 
a percent of total spores 
Wild-type 100 ± 12 68 ± 4 
gα1¯ 71 ± 32 74 ± 5 
 
  
 
 
Gα1 is important for CfaD binding to cells  
 Previous work found that rAprA had saturatable binding to Dictyostelium cells 
(41, 43). rCfaD was incubated with wild type cells to determine if it also had saturatable 
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binding. We found that rCfaD has saturatable binding to wild type cells (Figure 21). 
gα1¯ cells were analyzed for their ability to bind rCfaD, as the cells are insensitive to 
rCfaD proliferation inhibition (data not shown). gα1¯ cells had similar binding of rCfaD 
compared to wild type cells with no difference in KD or Bmax (Figure 21). Together, 
these data indicate that rCfaD can bind to Dictyostelium cells and that gα1¯ cells have 
similar binding properties to wild type cells.  
 
 
 
Figure 21: The effect of Gα1 on CfaD binding. Cells were incubated with various 
concentrations of rCfaD for 10 minutes, collected, and analyzed for bound rCfaD with anti-myc 
antibodies. Values are mean ± SEM. Curves are fit to one-site specific binding.  
 
 
 
Gα1, Gα8, Gα9, and Gβ are required for GTPγS inhibition of CfaD binding 
The addition of non-hydrolyzable GTPγS to membranes can affect ligand 
binding (196). When GTPγS is used Gα subunits remain bound to GTP in the active 
state (196). Wild type membranes were incubated with rCfaD in the presence or absence 
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of GTPγS. Wild type membranes bound rCfaD and binding was reduced by ~40% in the 
presence of GTPγS (Figure 22). The same assay was repeated with gα1¯, gα8¯, gα9¯, 
and gβ¯ cells to determine which of these are necessary for CfaD signaling through G 
proteins. The addition of GTPγS had no effect on any of the mutant cell lines (Figure 
22). Together, the data suggest that Gα1, Gα8, Gα9, and Gβ are required for CfaD 
signaling through G proteins.  
 
 
 
Figure 22: The effect of GTPγS on CfaD binding. Cell membranes were incubated with rCfaD 
in the presence or absence of GTPγS. Values shown are percentage change compared to no 
added GTPγS. Values are mean ± SEM (n ≥ 3). * indicates p <0.05 (t-test).  
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Discussion 
 Here, the chalone CfaD has been found to bind Dictyostelium cells to saturation. 
gα1¯ cells have faster proliferation, but no role in the growth of cells. gα1¯ cells are also 
multinucleate, have normal proliferation on bacterial lawns, slow colony expansion, and 
develop normal, viable spores. rCfaD sensitivity is lost in gα1¯ cells, although gα1¯ 
cells have normal cell binding of rCfaD. GTPγS reduces the binding of rCfaD to cell 
membranes, and this requires Gα1, Gα8, Gα9, and Gβ. Together, this indicates that CfaD 
uses G proteins to induce signaling and Gα1, Gα8, Gα9, and Gβ are necessary for this 
process.  
 Gα1 is expressed a low levels in vegetative Dictyostelium cells and increased 
throughout development (200). Overexpression of Gα1 in wild type cells results in a 
multinuclear phenotype and did not result in inhibition of proliferation (198). This is a 
phenotype we have seen with other AprA/CfaD signaling components (132). Gα1 
mutants do not affect spore viability, unlike CfaD mutant cells. Gα1 is insensitive to 
rCfaD proliferation inhibition, but has normal rCfaD binding. GTPγS did not reduce the 
ability of rCfaD to bind cells in gα1¯ cells. This suggests that Gα1 is involved in CfaD 
signaling as the reduction in GTPγS binding is lost with the loss of Ga1. Together, these 
data indicate that Gα1 in required for rCfaD signaling and mediates some, but not all of 
CfaD effects.  
 Gα8 is expressed throughout Dictyostelium cell vegetation and development 
(201). gα8¯ cells have rapid proliferation and overexpression of Gα8 inhibits cell 
proliferation (43, 198). Gβ is essential for Gα8-induced proliferation inhibition (198). 
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Ga8 is required for AprA signaling (43). Gα8 mediates some, but not all of the 
phenotypes of AprA, many of which are shared by CfaD (43). This indicates that Gα8 
also mediates some of the CfaD phenotypes. Gα8 appears to be required for CfaD 
signaling as reduction in GTPγS binding is lost in cells lacking Gα8. Together, this 
indicates that both AprA and CfaD signal through Gα8.  
  Gα9 is also expressed during Dictyostelium vegetation and development (202). 
Gα9 is known to inhibit chemotaxis and couple to the G protein-coupled receptor, GrlE 
(202-204). Conflicting evidence for the role of Gα9 has been presented. Gα9 is not 
involved in the proliferation inhibition of AprA (43). Gα9 has been suggested to be 
involved in regulation of proliferation through an interaction with Rgb-3, in which 
mutants display fast proliferation (205). Gα9 appears to be necessary for CfaD signaling. 
The requirement of AprA for CfaD signaling may explain the previous observation that 
Gα9 was not needed for AprA signaling, but insensitive to proliferation inhibition by 
AprA. Gα9’s role in AprA signaling could be indirect through CfaD signaling. Together, 
these data indicate that Gα9 is required for CfaD-induced proliferation inhibition.  
 Gβ, which is expressed in vegetative and developing cells, is necessary for AprA 
signaling (43). We observed that Gβ is also necessary for CfaD signaling increasing the 
evidence that CfaD signals through G proteins.  
 
Conclusions and future directions 
We observed that CfaD requires three Gα proteins, Gα1, Gα8, and Gα9 and Gβ 
to induce proliferation inhibition in Dictyostelium cells. Combined with previous work, 
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this provides evidence for convergent and divergent signaling in the AprA and CfaD 
signaling pathways. Both AprA and CfaD require Gα8 and Gβ for signaling, while CfaD 
additionally needs Gα1 and Gα9. This strengthens the evidence for multiple branched 
pathways of AprA and CfaD signaling. Future work will look at additional properties of 
Gα1, examine the rescue of gα1¯ cells, and determine the effect of CfaD binding on 
[H3+] GTP recruitment to the membrane of Dictyostelium cells.   
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APPENDIX C 
THE DICTYOSTELIUM CHALONES APRA AND CFAD USE G PROTEIN-
COUPLED RECEPTORS TO SIGNAL PROLIFERATION INHIBITION 
 
Summary 
Previous work in our lab had found that AprA functions through the Gα8 protein. 
Work in the previous appendix suggests that CfaD also signals through a Gα protein, 
Gα1. The receptor(s) for AprA and CfaD signaling are unknown. This previous data 
suggests that AprA and CfaD may signal using G protein-coupled receptors (GPCRs). 
Eight mutant GPCR strains were a gift from Dr. Janetopoulos. These eight GPCR 
mutants were analyzed to determine their role in AprA and/or CfaD signaling of 
proliferation inhibition and additionally their role in AprA chemorepulsion signaling. 
The work in this appendix focuses on identifying if any of the GPCR mutants are the 
receptor(s) for AprA and CfaD signaling. GrlB, GrlE, and GrlH are candidates for 
proliferation inhibition signaling while GrlB and GrlH are candidates for 
chemorepulsion signaling.  
Two undergrads, Francisco Brito and Jose Ting, have helped with the analysis of 
these GPCR mutants. 
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Introduction 
Chalones are secreted factors that inhibit the proliferation of the cells that secrete 
them (1, 2). Melanocyte proliferation can be inhibited by an unknown secreted factor 
(18, 19). When the chalone is injected under the skin of melanomas, the proliferation 
ceases (18, 19). Despite its action, the chalone and the signaling pathway used to inhibit 
proliferation remain a mystery. In fact, the identity of most predicted chalones and their 
signaling pathways are unknown.  
We have previously identified two Dictyostelium chalones, AprA and CfaD. 
Both are secreted proteins that inhibit Dictyostelium cell proliferation (39, 40). Lacking 
AprA or CfaD results in faster proliferation, which returns to wild-type levels by either 
rescuing the mutant or the addition of recombinant proteins to the mutant strains (39-41). 
Both AprA and CfaD are necessary for proliferation inhibition as recombinant AprA 
(rAprA) cannot rescue the cfaD¯ phenotype and recombinant CfaD (rCfaD) cannot 
rescue the aprA¯ phenotype (41, 43). Several components of the AprA and/or CfaD 
signaling pathway have been identified including the transcription factor BzpN, the 
ROCO kinase QkgA, the PTEN-like protein CnrN, and the tumor suppressor RblA (45-
47, 132). Additionally, AprA functions to chemorepulse Dictyostelium cells (48). Wild 
type cells move in a biased direction away from a source of AprA (48). AprA 
proliferation and chemorepulsion signaling require the Gα protein Gα8, suggesting that 
AprA functions through a G protein-coupled receptor (GPCR) (43, 48).  
GPCRs are comprised of 7 transmembrane α-helicies that interact with 
heterotrimeric G proteins upon stimulation from a ligand (197). G proteins have three 
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subunits, Gα, Gβ, and Gγ that relay the initial signal to numerous downstream effectors 
(206). GPCR signaling is important for many cellular processes including proliferation 
and chemotaxis. When a signal activates a GPCR, the Gα subunit dissociates from the 
Gβγ subunit and each can initiate signaling cascades (206). Gβγ subunits are known to 
activate phosphatidylinositol 3-kinase (PI3K) (206). PI3K phosphorylation of the 
membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 
3,4,5-trisphosphate (PIP3) recruits proteins such as Akt which regulates cell proliferation 
(113, 120, 122-124). Additionally, activation of PI3K, and subsequently PIP3, leads to 
promotion of actin remodeling (38, 51, 58-60). Polarization of PIP3 and actin remodeling 
at one end of the cell induces pseudopodia formation and chemotaxis (38, 58-60).  
Here we have examined eight GPCR mutants in Dictyostelium. We have 
analyzed the mutants for sensitivity to AprA and CfaD. We have identified that GrlB, 
GrlE, and GrlH are candidates for proliferation inhibition signaling and GrlB and GrlH 
are candidates for chemorepulsion signaling.  
 
Methods  
 grlB−, grlD−, grlE−, grlH−, fslA−, fslB−, fslK−, and fscE− cells were a gift from 
Dr. Janetopelous. Wild-type and mutants were grown as previously described (192). 
Proliferation in shaking culture and on bacterial plates, proliferation inhibition, 
chemotaxis, nuclei, mass and protein, colony expansion, and spore viability were all 
done as previously described (46, 132). Colony edge assays were done as previously 
described except that 200 µl of HL5 media without bacteria was added to each well (46). 
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Quantification of movement at the colony edge was determined by measuring the 
distance traveled of 30 randomly chosen cells per strain. All statistics were done with 
significance determined as p < 0.05 using Prism Graphpad software (San Diego, CA). 
 
Results 
Several GPCR mutants exhibit fast proliferation phenotypes 
AprA and Cfad mutant cells exhibit faster proliferation compared to wild type 
cells, resulting in a faster doubling time and a higher maximum density (39, 40). We 
examined GPCR mutants for a faster proliferation phenotype. Two mutants, grlE− and 
grlH−, had a significantly faster doubling time when compared to wild type (Figure 23). 
Two mutants, grlB− and fslA−, has slightly higher maximum densities compared to wild 
type, although these values were not significant (Table 15). One mutant, grlD−, had a 
significantly lower maximum cell density compared to wild type cells. The remaining 
mutants were similar to wild type in both doubling time and maximum cell density. This 
suggests that some GPCR mutants exhibit the fast proliferation phenotype we would 
expect to see when a component of the AprA and/or CfaD pathways is eliminated or 
defective.  
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Figure 23: The effect of GPCR mutants on proliferation. Log phase cells were started at 1 x 
105 cells.ml and counted daily. Data from (A) fast proliferation mutants and (B) normal or slow 
proliferation mutants was taken simultaneously. Values are mean ± SEM, n ≥ 3.   
 
 
 
Accumulation of AprA and CfaD in GPCR mutant media 
 One reason a mutant Dictyostelium strain would have varied proliferation from 
wild type cells is a change in the accumulation of AprA or CfaD. An increase in AprA or 
CfaD accumulation would result in slower proliferation as these proteins both inhibit cell 
proliferation. A decrease in AprA or CfaD accumulation would result in faster 
proliferation. The conditioned media from GPCR mutants were analyzed for the 
concentrations of extracellular AprA and CfaD. All but two strains had normal 
accumulation of AprA and CfaD (Figure 24). fscE− cells had a higher accumulation of 
AprA. grlD− cells had higher accumulation of both AprA and CfaD. None of mutants 
accumulated less AprA or CfaD. Together these data indicate that the faster proliferation 
observed in several of the mutant strains is not due to less accumulation of AprA or 
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CfaD and that the slower proliferation of some mutants may be explained by an increase 
in AprA and/or CfaD accumulation.  
 
 
  
Table 15. The effect of GPCRs on doubling time and stationary density. Doubling times and 
maximum cell densities were calculated using the data in Figure 23A and B. Values are mean ± 
SEM, n ≥ 3. Statistical significance compared to wild type is shown as * (p < 0.05) and ** (p < 
0.01) (one-way ANOVA). 
  
Cell Type Doubling time, 
hours 
Maximum observed 
cell density, 10
5
 
cells/ml 
Wild-type 14.1 ± 0.8 186 ± 20.6 
grlB¯ 12.1 ± 1.2 234 ± 15.3 
grlD¯ 14.3 ± 1.3 89.8 ± 6.3** 
grlE¯ 10.8 ± 0.9* 188 ± 16.5 
grlH¯ 8.9 ± 1.7* 198 ± 22.4 
fslA¯ 13.7 ± 1.2 221 ± 41.9 
fslB¯ 15.4 ± 1.0 136 ± 12.8 
fslK¯ 14.8 ± 1.4 137 ± 11.8 
fscE¯ 11.4 ± 0.7 120 ± 8.41 
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Figure 24: Accumulation of AprA and CfaD in GPCRs mutants. Conditioned media from 
mid-log phase cells was analyzed for accumulated (A) AprA and (B) CfaD using anti-AprA and 
anti-CfaD antibodies. Quantifications (n=3, mean ± SEM) of western blot bands are shown. * 
and ** indicate statistical significance from wild type accumulation with p < 0.05 and p < 0.01, 
respectively (one-way ANOVA).  
 
 
 
Several GPCR mutants are insensitive to AprA and CfaD 
 We would expect when components of the AprA and CfaD pathways are 
knocked out, the mutant strains would be insensitive to AprA and/or CfaD. Thus, the 
addition of AprA and CfaD should not be able to slow the proliferation of cells. No 
difference in cell proliferation was observed for grlH− cells in response to CfaD, fslB− 
and fscE− cells in response to AprA, or fslA− and fslK− cells in response to either AprA 
or CfaD (Figure 25). fslB− and fscE− cells were insensitive to only CfaD and grlH− cells 
were insensitive to only AprA. grlB−, grlD−, and grlE− cells were insensitive to both 
AprA and CfaD. Together, with the data from previous sections, these data indicate that 
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GrlB and GrlE may be candidates for AprA and CfaD signaling and GrlH for AprA 
signaling only.  
 
 
 
 
Figure 25: Sensitivity of GPCRs to rAprA and rCfaD. 300 ng/ml rAprA or rCfaD or an 
equivalent volume of buffer was added to cell cultures which were left for 16 hours before cell 
densities were determined. Percent inhibition of proliferation in (A) rAprA or (B) rCfaD 
compared to the buffer control proliferation is shown. Mean ± SEM, n ≥ 3. *, **, and *** 
indicate p < 0.05, p < 0.01, and p < 0.001, respectively (one-way ANOVA).  
 
 
 
grlD−, grlH−, and fslK− cells are multinucleate 
 Both AprA and CfaD mutants are more multinucleate than wild type cells (39, 
40). To determine if any of the mutants exhibited this phenotype, cells were stained with 
DAPI and their nuclei counted. grlD−, grlH−, and fslK− cells had significantly less cells 
with a single nucleus than wild type cells (Table 16). Both grlH−and fslK− cells had 
significantly more cells with two nuclei and fslK− cells had significantly more cells with 
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three or more nuclei. These data indicate that like AprA and CfaD, several GPCR 
mutants are more multinucleate than wild type.  
 
The screened GPCRs have no effect on cell growth 
 AprA and CfaD affect the proliferation of cells, but not cell growth, which is 
defined as an increase in mass and protein (39, 40). Mutant GPCR strains were analyzed 
for their mass and protein content. grlD−, fslA−, fslB−, fslK−, and fscE− cells had 
increased amounts of protein compared to wild type cells (Table 17). grlH− cells had 
significantly less protein than wild type cells (Table 17). grlD−, grlH−, and fslK− had 
more nuclei per 100 cells than wild type cells (Table 17). Mass and protein contents 
were adjusted for the number of nuclei per 100 cells for each strain. When protein 
content was adjusted, all mutant strains had a similar amount of protein as wild type 
cells (Table 17). There were no differences in cell mass.  
 The accumulation of mass, protein, and nuclei are a function of their proliferation 
rate. A doubling of cell number should then result in a doubling of mass, protein, and  
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Table 16. The effect of GPCR on nuclei per cell. Cells with one, two, or three or more nuclei 
were counted. *, **, *** indicate statistical significance compared to wild type with p < 0.05, p 
< 0.01, and p < 0.001, respectively (one-way ANOVA). Values are mean ± SEM, n=3.  
 
 
 Percent of cells with n nuclei 
Cell Type 1 2 3+ 
Wild-type 79 ± 3.5 20 ± 3.6 0.6 ± 0.2 
grlB¯ 76 ± 2.6 22 ± 1.8 1.8 ± 0.6 
grlD¯ 62 ± 3.1** 34 ± 1.7* 3.7 ± 1.9 
grlE¯ 79 ± 4.3 20 ± 3.9 0.8 ± 0.6 
grlH¯ 55 ± 4.1*** 40 ± 3.4*** 4.3 ± 0.8 
fslA¯ 69 ± 3.7 27 ± 2.6 4.1 ± 2.2 
fslB¯ 71 ± 2.3 27 ± 1.7 2.4 ± 0.6 
fslK¯ 49 ± 3.8*** 41 ± 3.1*** 9.4 ± 1.6*** 
fscE¯ 71 ± 1.3 29 ± 1.2 0.9 ± 0.3 
 
 
 
 
nuclei. The doubling times from Table 15 were used to calculate the accumulation of 
mass, protein, and nuclei. Compared to wild type cells, none of the mutant strains had 
differences in mass accumulation. fscE− cells accumulated significantly more protein per 
hour than wild type cells, but there was no difference in protein accumulation per nuclei 
per hour between wild type and fscE− cells (Table 18). There were no other differences  
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Table 17. The effect of GPCRs on the mass and protein content of cells. Mass and protein 
content of GPCR mutants was measured. Data from Table 16 was used to calculate the nuclei 
per 100 cells. Nuclei per 100 cells was used to calculate the mass and protein content per 107 
nuclei. *, **, and *** indicate values are statistically significant from wild type with p < 0.05, p 
< 0.01, and p < 0.001, respectively. Values are mean ± SEM, n ≥ 3.  
 
 
 
 
in protein accumulation. grlH− cells accumulated more nuclei per hour than wild type 
cells. Together these data indicate that none of the mutants play a significant role in the 
growth of cells.   
 
 
 
 
 
 Per 107 cells  Per 107 nuclei 
Cell 
type 
Mass 
(mg) 
Protein (mg) Nuclei/100 
cells 
Mass 
(mg) 
Protein 
(mg) 
Wild-
type 
15.4 ± 2.9 1.10 ± 0.02 121 ± 3 12.6 ± 2.3 0.91 ± 0.21 
grlB¯ 20.8 ± 5.0 1.21 ± 0.02 126 ± 3 16.4 ± 4.0 0.96 ± 0.21 
grlD¯ 19.3 ± 3.4 1.55 ± 0.02*** 143 ± 5* 13.5 ± 2.4 1.09 ± 0.02 
grlE¯ 14.2 ± 1.6 1.15 ± 0.01 122 ± 5 11.7 ± 1.3 0.95 ± 0.00 
grlH¯ 13.3 ± 1.0 0.98 ± 0.01* 150 ± 5** 8.9 ± 0.6 0.66 ± 0.01 
fslA¯ 17.2 ± 3.0 1.31 ± 0.03*** 136 ± 6 12.7 ± 2.2 0.97 ± 0.03 
fslB¯ 14.0 ± 2.4 1.46 ± 0.06*** 132 ± 3 10.7 ± 1.8 1.11 ± 0.05 
fslK¯ 17.4 ± 3.0 1.60 ± 0.03*** 167 ± 9*** 10.4 ± 1.8 0.96 ± 0.02 
fscE¯ 14.7 ± 1.7 1.33 ± 0.03*** 131 ± 2 11.3 ± 1.3 1.02 ± 0.02 
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Table 18. The effect of GPCRs on mass and protein accumulation of cells. Doubling times 
from Table 15 were used to determine mass, protein, and nuclei accumulation per hour. Mean ± 
SEM, n ≥ 3. Values are statistically significant from wild type at * with p < 0.05 and ***with p < 
0.001. 
 
 Per 107 cells/hour  Per 107 nuclei/hour 
Cell type Mass (mg) Protein (µg) Nuclei, x 10
-5
 Mass (mg) Protein (µg) 
Wild-
type 
1.09 ± 0.21 78 ± 5 8 ± 1 0.90 ± 0.18 65 ± 4 
grlB¯ 1.72 ± 0.45 100 ± 10 10 ± 1 1.36 ± 0.36 80 ± 8 
grlD¯ 1.35 ± 0.27 109 ± 10 10 ± 1 0.94 ± 0.19 76 ± 8 
grlE¯ 1.31 ± 0.19 106 ± 9 11 ± 1 1.08 ± 0.16 87 ± 8 
grlH¯ 1.49 ± 0.31 110 ± 21 17 ± 3*** 0.99 ± 0.21 73 ± 14 
fslA¯ 1.26 ± 0.24 96 ± 8 9 ± 1 0.93 ± 0.18 70 ± 7 
fslB¯ 0.91 ± 0.17 95 ± 7 9 ± 1 0.69 ± 0.13 72 ± 6 
fslK¯ 1.18 ± 0.23 108 ± 10 11 ± 1 0.71 ± 0.14 65 ± 7 
fscE¯ 1.28 ± 0.17 116 ± 8* 11 ± 1 0.98 ± 0.13 89 ± 6 
 
 
 
 
Several GPCRs are important for spore development 
 The cost of lacking AprA or CfaD is a defect in spore viability, suggesting these 
proteins help regulate spore survivability (39, 40). grlD−, fslA−, and fscE− cells have a 
reduced ability to produce spores during development and their spores are less viable 
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than wild type spores (Table 19). Although grlE−, fslB−, and fslK− cells can produce a 
normal number of spores, the spores are less viable than wild type spores (Table 19). 
These data suggest that multiple GPCRs may be required for Dictyostelium spore 
development and viability.  
 
 
 
 
 
Table 19. The effect of GPCRs on spore development and viability. Percent of visible spores 
following 48 hours of developed were calculated from the input cells. Spores were treated with 
detergent, plated, and viable colonies were counted. Values are mean ± SEM, n=3 . ** and *** 
indicates differences are significantly different compared to wild-type with p < 0.01 and p < 
0.001, respectively (one-way ANOVA).  
 
 
Cell Type Viable spores after development 
as a percent of input cell number 
Detergent resistant spores as a 
percent of total spores 
Wild-type 122 ± 11 124 ± 15 
grlB¯ 82 ± 16 127 ± 11 
grlD¯ 0.38 ± 0.20*** 34 ± 16*** 
grlE¯ 96 ± 20 47 ± 18** 
grlH¯ 148 ± 27 105 ± 16 
fslA¯ 0.14 ± 0.05*** 62 ± 3** 
fslB¯ 60 ± 20  15 ± 6*** 
fslK¯ 124 ± 8 14 ± 3*** 
fscE¯ 24 ± 12** 39 ± 4*** 
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Expansion of GPCR mutant colonies 
 aprA− cells have slowly expanding colonies and this slow expansion is not due to 
a defect in motility (46). The expansion of GPCR mutant colonies was measured daily. 
grlB−, grlH−, fslA−, fslB−, and fslK− colonies expanded slower than wild type cells as 
these colonies were smaller than wild type colonies on days 4, 5, and 6 (Figure 26). 
grlD− colonies were smaller than wild type colonies on day 4, but were similar to wild 
type colonies on all other days. fscE− colonies expanded similarly to wild type colonies 
but were significantly smaller on day 6. Slow colony expansion in grlH−, fslA−, fslB−, 
and fslK− colonies may be due to slower motility seen in these strains (data not shown). 
GrlB may play a role in chemorepulsion as it has a slower expansion not due to a defect 
in cell motility. 
 
Several GPCRs appear to be necessary for AprA chemorepulsion 
 Wild type cells move in a biased direction away from a source of AprA (48). We 
tested the ability of GPCR mutant cells to be chemorepulsed by AprA. As we have 
previously seen, wild type cells moved in a biased direction away from AprA (48). 
Likewise, grlE−, fslA−, and fslK− mutants respond to and move away from AprA (Figure 
27). grlB−, grlD−, grlH−, and fslB− are all insensitive to GPCRs may play a role in AprA 
chemorepulsion.  
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Figure 26: GPCR mutant colony expansion. Approximately 10 cells were plated onto plates 
containing K. aerogenes bacteria. At least 3 colonies were measured per time plate. After 6 days, 
individual wild type colonies were indistinguishable from each other. Values are mean ± SEM, n 
≥ 3. The absence of error bars indicates the SEM was less than the size of the marker.   
 
 
  
GrlB and GrlH are involved in cell dispersal at the edge of colonies 
Cells at the edge of wild type colonies tend to move away from the cell dense 
center, while cells of an AprA mutant colony do not (46). AprA mutant colonies form a 
tight edge line (46). We screened GPCR mutant cells for their ability to spread out from 
the colony center. We would expect mutants of the AprA chemorepulsion pathway to 
display tight colony edges. As we have previously seen, wild type cells move away from 
the edge of colonies (46). grlH− and grlB− cells did not move outward from the dense 
colony center (Figure 28). The remainder of mutant cells spread away from the center  
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Figure 27:  The effect of AprA on chemorepulsion in GPCR mutants. rAprA solution or an 
equivalent volume of buffer was added to one side of an Insall Chamber. Videomicroscopy was 
used to visualize the movement of cells which were then manually tracked. Migration along the 
x-axis is shown in microns (mean ± SEM, n ≥ 3). *, **, and *** indicate p < 0.05, p <0.01, and 0 
< 0.001, respectively (t-test).  
 
 
of the colony similar to wild type. These observations were supported by the average 
distances cells at the edge of colonies move. Cells at the edge of grlH− and grlB− 
colonies traveled significantly less distance than cells at the edge of wild type colonies 
(Table 20). These data indicates that GrlB and GrlH are good candidates for AprA 
signaling.  
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Figure 28: Colony edge formation of GPCR mutants. Colonies of cells were allowed to 
adhere to glass well slides. Fresh media was added to the wells and cells were left overnight to 
spread. The edges of colonies were imaged with a 20x phase contrast objective. The right colony 
edge is shown for all strains except fslA¯ where the top colony edge is shown. Images are 
representative of at least three individual experiments.  
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Table 20. Distance traveled away from colony edge. The distance traveled from the colony 
edge at least 30 randomly chosen cells was measured from Figure 28 and data not shown. Values 
are mean ± SEM. *** indicates p < 0.001 (one-way ANOVA).  
 
Cell Type Average distance from 
colony edge (microns) 
Wild-type 52 ± 7 
grlB¯ 16 ±3*** 
grlD¯ 68 ± 7 
grlE¯ 31 ± 4 
grlH¯ 11 ± 1*** 
fslA¯ 36 ± 4 
fslB¯ 37 ± 5 
fslK¯ 61 ± 12 
fscE¯ 42 ± 5 
 
 
 
 
Discussion 
 In this section of the dissertation, I have characterized eight GPCRs and their 
sensitivity to AprA and CfaD. Here, I show that there are several candidates that may 
play a role in AprA and/or CfaD signaling. GrlB, GrlE, and GrlH are strong candidates 
for proliferation inhibition, while GrlB and GrlH are also candidates for chemorepulsion 
signaling.  
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 Several mutants displayed proliferation slower than wild type. The slower 
proliferation of fscE− cells was due to an increased accumulation of AprA. Intriguingly, 
grlD− cells had significantly slower proliferation and increased accumulation but were 
insensitive to AprA and CfaD inhibition. grlD− cells were also found to be more 
multinucleate than wild type cells. Within the time course of 16 hours a defect in 
cytokinesis could explain why grlD−cells appeared to be insensitive to AprA and CfaD. 
grlD− cells contained more protein than wild type cells. When protein was corrected for 
the multinuclear phenotype, grlD− cells had similar amounts of protein to wild type 
cells. Additionally, grlD− cells have a significant defect in spore production and 
viability. This suggests that grlD− cells have an overall defect in proliferation, possibly 
due to cytokinesis disruption and viability. GrlD may be important for normal cellular 
function including viability.  
 GrlB, GrlE, and GrlH appear to be candidates for proliferation inhibition 
signaling. grlE−and grlH− cells have significantly faster doubling times and grlB− 
reaches a higher density than wild type cells. These are both phenotypes we have 
previously seen independent of each other for certain AprA and CfaD signaling 
components (45, 47). The increase in proliferation for these mutants was not due to 
higher accumulation of AprA or CfaD. Additionally, all three mutant strains were 
insensitive to the addition of AprA and grlB− and grlE− cells were insensitive to CfaD. 
Together this suggests that GrlB, GrlE, and GrlH are potential candidates for 
proliferation inhibition signaling components.  
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grlB−, grlD−, grlH−, and fslB− appear to be insensitive to AprA chemorepulsion 
signaling. The edges of grlB− and grlH− colonies are tight while the edges of grlD− and 
fslB− cells disperse similar to wild type cells. This suggests that grlD− and fslB−cells can 
sense AprA and move outward at the colony edge. The insensitivity to rAprA may be an 
artifact in these strains or due to their slow motility. Together the data indicate that GrlB 
and GrlH are candidate components of AprA chemorepulsion signaling. 
 
Conclusions and future directions 
The work in this dissertation appendix shows that GrlB, GrlE, and GrlH are 
potential candidates for proliferation inhibition through AprA and CfaD while GrlB and 
GrlH are candidates for chemorepulsion signaling through AprA. Future work on these 
GPCRs should focus on rescuing the potential candidates to show that specific 
phenotypes are due to loss of the gene. Additionally, expressing the receptors in a 
heterologous system would allow us to study the binding of rAprA and rCfaD to these 
receptors.   
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APPENDIX D 
PERITONEAL DIALYSIS FLUID AND SOME OF ITS COMPONENTS  
POTENTIATE FIBROCYTE DIFFERENTIATION 
 
Summary 
Work in this appendix was done as side project working with peripheral blood 
mononuclear cells, which our lab uses to study wound healing. Much of the intellectual 
design for the work in this section is credited to Katayoon Keyhanian when she brought 
the idea of studying fibrosis in dialysis patients. Additionally, and undergrad, Hannah 
Starke helped with a portion of the experiments within this section.  
Long-term peritoneal dialysis often results in the development of peritoneal 
fibrosis. Submesotheium thickening, increased extracellular matrix deposition, and 
increased fibrotic tissue characterize peritoneal fibrosis. For many fibrosing diseases, 
monocytes enter the fibrotic lesion and differentiate into fibroblast-like cells called 
fibrocytes, which contribute to fibrosis. Peritoneal dialysis (PD) fluids contain glucose, a 
number of electrolytes, and buffers. Recently, high sodium chloride has been associated 
with an increase in fibrocyte differentiation. We report that PD fluid potentiates human 
fibrocyte differentiation in vitro and that sodium chloride and sodium lactate are 
responsible for this potentiation. In addition, PD fluid and sodium chloride decrease the 
ability of the plasma protein Serum Amyloid P (SAP) to inhibit fibrocyte differentiation. 
Together, these results suggest that PD fluid components contribute to the development 
of peritoneal fibrosis, and their ability to desensitize the SAP response may exacerbate 
the disease.  
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Introduction 
 For patients with end stage renal disease, the kidneys no longer function to 
properly remove wastes from the body (207). Peritoneal dialysis (PD) is the most cost-
effective and easiest therapy available to replace kidney function (208-211). PD fluids 
contain a mixture of electrolytes to help maintain blood composition, an osmotic agent 
to facilitate the transport of water and other liquids through a membrane, and a buffer to 
maintain proper pH (209, 210). The commonly used peritoneal dialysis fluid Dianeal® 
contains the electrolytes sodium, chloride, calcium, and magnesium, the sugar D-glucose 
as an osmolyte, and a buffer containing lactate. PD fluid is injected via a permanent 
catheter into the peritoneal cavity (208, 212). The peritoneal membrane acts as a 
dialyzing membrane, allowing the removal of waste products from the body (210-212). 
Although peritoneal dialysis has many advantages to other treatments, the development 
of tissue remodeling such as angiogenesis, fibrosis and membrane failure are debilitating 
disadvantages (208, 210-214).  
   Peritoneal fibrosis is characterized by a thickening of the submesothelium, 
increased extracellular matrix deposition, the presence of myo-fibroblasts, and increased 
fibrotic (scar) tissue (208, 210-214). During an inflammation response, leukocytes leave 
the blood to the affected organ and may differentiate into fibroblast-like cells called 
fibrocytes (215). Like fibroblasts, fibrocytes can aid in wound healing by promoting scar 
tissue formation (215-217). Fibrocytes differentiate from CD14+ monocytes and share 
characteristics of both blood leukocytes and tissue resident cells (218, 219). Fibrocytes 
can promote angiogenesis and secrete inflammatory cytokines and extracellular matrix 
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proteins (215, 220). Serum amyloid P (SAP) is a pentraxin protein, secreted by the liver 
into the plasma, which inhibits fibrocyte differentiation (216). The presence of 
fibroblasts in peritoneal fibrosis has been well documented, however the presence of 
fibrocytes has not (214, 221-225). 
 A number of factors including the presence of a catheter, uremia, peritonitis, and 
the PD fluid itself can contribute to development of peritoneal fibrosis. Glucose 
degradation products (GDP) (including 5-hydroxymethylfuraldehyde and 3,4-
dideoxyglucosone-3-ene) that form during heat sterilization of the PD fluid have an 
adverse effect on the peritoneal membrane and can promote fibrosis. Recent studies 
using low-GDP fluids show a decrease in peritonitis however, they did not report 
whether peritoneal fibrosis was still observed in these patients. Although the effects of 
GDPs in PD fluid have been analyzed, little has been done to determine the effects of the 
remaining components of PD fluid.  
 In this report, we examine the effects of PD fluid and components of PD fluid on 
fibrocyte formation. Previously, we found that increased sodium chloride potentiates the 
differentiation of monocytes into fibrocytes (226). Our results indicate that PD fluid 
components sodium chloride and sodium lactate potentiate fibrocyte differentiation and 
the potentiation is not inhibited by SAP.  
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Methods 
Cell culture and fibrocyte differentiation assays 
Human blood was collected into heparin tubes (BD Bioscience, San Jose, CA) 
from adult volunteers who gave written consent and with specific approval from the 
Texas A&M University human subjects Institutional Review Board. Peripheral blood 
mononuclear cells (PBMC) were isolated as previously described (227).  
PBMC were cultured in 96-well cell plates (Falcon) with peritoneal dialysis fluid 
(132 mM sodium, 96 mM chloride, 3.5 mM calcium, 0.5 mM magnesium, 40 mM 
lactate, and 1.5% D-glucose) or individual components of PD fluid (sodium chloride, 
calcium chloride, magnesium chloride, sodium lactate, or D-glucose) in RPMI-1640 
medium. One molar solutions of sodium chloride, calcium chloride, magnesium 
chloride, D-glucose and sodium lactate were prepared in water and filter sterilized as 
previously described (226). Solutions were added to the wells at the indicated 
concentrations. 5 x 104 cells in 100 μL of RPMI-1640 were added to each well. Cells 
were incubated for five days with 5% CO2 at 37°C. Following incubation, cells were 
fixed with methanol for ten minutes and stained with a Hema 3 staining Kit (Thermo 
Fisher Scientific, Milwaukee, WI). Fibrocytes were identified by their spindle-shape 
morphology and counted in five 900-μm fields of view.  
SAP ranging from 5μg/mL to 0.04μg/mL was co-incubated with 12.5% PD fluid, 
12.5 mM sodium chloride, 5 mM sodium lactate (all in RPMI-1640), or RPMI-1640 
alone. Fibrocytes were incubated, stained, and counted as stated previously.  
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Collagen and DAPI Staining 
Collagen staining was done as previously described with the exception that the 
primary antibody was 2.5 µg/ml rabbit anti-collagen I (Abcam, Cambridge, MA) (228).   
 Plates from the fibrocyte differentiation assays were stained with 2 µg/ml DAPI 
(Sigma Aldrich), imaged, and analyzed with CellProlifer analysis software (229).  
 
Statistics 
Data were analyzed using t-tests and calculating IC50s with Prism (GraphPad 
software, San Diego, CA). 
 
Results 
PD fluid potentiates fibrocyte differentiation 
 The use of PD fluid is associated with peritoneal fibrosis, and fibrocytes 
contribute to fibrosis (212, 213, 216). To determine if PD fluid affects the differentiation 
of monocytes into fibrocytes, human PBMCs were incubated with various 
concentrations of PD fluid for 5 days. The number of fibrocytes present after 5 days in 
PD fluid was determined and normalized to the number of fibrocytes without PD fluid. 
In the presence of 12.5% PD fluid, the number of fibrocytes was significantly increased 
(Figure 29). [Na+] and [Cl-] are 134 mM and 107 mM, respectively in RPMI medium. In 
RPMI medium, 12.5% PD fluid corresponds to an additional 16.5 mM sodium and an 
additional 12 mM chloride, making the [Na+] 150.5 mM and the [Cl-] 119 mM. These 
concentrations are comparable to previous findings where sodium chloride potentiated 
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fibrocyte differentiation (226). [Ca2+] and [Mg2+] are 0.42 mM and 0.4 mM, respectively 
in RPMI medium. In RPMI medium, 12.5% PD fluid corresponds to an additional 0.44 
mM calcium and an additional 0.06 mM magnesium making the [Ca2+] 0.86 mM and the 
[Mg2+] 0.46 mM. A 0.18% addition of glucose from 12.5% PD fluid to the 0.2% in 
RPMI medium results in a total of 0.38% glucose. RPMI does not contain lactate, 
therefore the final concentration of lactate from 12.5% PD fluid is 5 mM. The number of 
fibrocytes was significantly decreased in the presence of 50% PD fluid. These results 
indicate that PD fluid can potentiate the differentiation of fibrocytes.  
 
Some, but not all, components of PD fluid potentiate of fibrocyte differentiation 
 PD fluid is composed of glucose, sodium chloride, magnesium chloride, calcium 
chloride, and sodium lactate. To determine which component(s) of PD fluid are 
responsible for the potentiation of fibrocyte differentiation, the individual components 
were incubated with PBMCs for 5 days. Glucose, calcium chloride, and magnesium 
chloride did not potentiate fibrocyte differentiation. Sodium chloride and sodium lactate 
potentiated fibrocyte differentiation at 12.5 mM and 5 mM, respectively (Figure 30). In  
RPMI medium, an additional 12.5 mM sodium chloride equals a [Na+] of 146.5 mM and 
a [Cl-] of 119.5 mM. These concentrations are similar to previous findings and to the 
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Figure 29: PD fluid potentiates the differentiation of fibrocytes. PBMC were incubated with 
the indicated concentrations of PD fluid for 5 days. The cells were then stained and counted. 
Values are mean ± SEM, n=6. * and *** indicate statistical significance with p < 0.05 and p < 
0.001, respectively (one-way ANOVA). 
 
 
 
concentrations in 12.5% PD fluid (226). An additional 5 mM sodium lactate in RPMI 
medium yields a [Na+] of 141 mM and a lactate concentration of 5 mM. Again, the 
sodium concentration is similar to previous observations where fibrocyte differentiation 
was potentiated (226).  
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Figure 30: The PD fluid components sodium chloride and sodium lactate potentiate 
fibrocyte differentiation. PBMC were incubated with the indicated PD fluid components with 
the indicated concentrations added to the medium for 5 days, after which cells were stained and 
counted. Values are mean ± SEM n=3. *, **, and *** indicate significant difference in fibrocyte 
numbers compared to control with p < 0.05, p < 0.01, and p < 0.001, respectively (t-test). The 
absence of an error bar indicates that the error was smaller than the plot symbol. 
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Figure 31: PD fluid and its components do not affect cell viability. PBMC were incubated 
with the indicated PD fluid components with the indicated concentrations added to the medium 
for 5 days, after which cells were stained and counted. Values are mean ± SEM n=3. The 
absence of an error bar indicates that the error was smaller than the plot symbol. 
 
 
 160 
 
One reason for the increase in fibrocyte number could be an increase in the 
number of adherent cells. After counting the number of fibrocytes, plates were stained 
with DAPI and the total number of viable adherent cells was analyzed via Cell Profiler. 
There was no significant increase or decrease in adherent cells that could attribute for the 
increase of fibrocytes (Figure 31). Together these data indicate that some, but not all, of 
the components of PD fluid potentiate fibrocyte differentiation. 
 
The expression of collagen is increased by PD fluid, sodium chloride, and sodium 
lactate  
Collagen is expressed by fibrocytes and used as a marker of these cells (228, 
230). To verify that the cells we counted were indeed fibrocytes, PBMCs were cultured 
with PD fluid, sodium chloride, or sodium lactate for 5 days. The cells were then stained 
for collagen I and analyzed by flow cytometry. PD fluid, sodium chloride, and sodium 
lactate all significantly increased the expression of collagen in these cells compared to 
cells in buffer alone (Figure 32). The presence of increased collagen in the cells indicates 
that PD fluid, sodium chloride, and sodium lactate potentiate fibrocyte differentiation.   
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Figure 32: PD fluid, sodium chloride, and sodium lactate increase the expression of 
collagen. Cells were stained with polyclonal rabbit antibodies for collagen I. A) Forward and 
side scatter properties of 5 day cultured cells. Histograms show the fluorescent intensities of 
rabbit IgG control (black line) and collagen I (red line) for media alone (B), PD fluid (C), 
sodium chloride (D), and sodium lactate (E). F) The total number of collagen positive cells was 
calculated from the percentage of positive cells within the region P1. Values are mean ± SEM, 
n≥3. *, p < 0.05; **, p < 0.01 (t-test).  
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PD fluid and some of its components effect the sensitivity of SAP 
SAP is secreted from the liver and inhibits fibrocyte differentiation (156, 216, 
231). PBMC were incubated with or without SAP in the presence of PD fluid, sodium 
chloride, and sodium lactate at the concentrations that caused the highest potentiation of 
fibrocytes (Figure 33). IC50 values showed that PD fluid and sodium chloride 
significantly desensitized PBMC to SAP (Table 21). Although sodium lactate with SAP 
had an increased IC50 compared to SAP alone, the difference was not significant. These 
data indicate that PD fluid and sodium chloride interfere with the ability of SAP to 
inhibit fibrocyte differentiation, while sodium lactate only potentiates fibrocyte 
differentiation.  
 
 
 
Table 21: IC50 values for PD fluid, sodium chloride, and sodium lactate in the presence of 
SAP. IC50 values were obtained by fitting a sigmoidal dose response curve to the data from 
Figure 33. Values mean ± SEM. ** indicates a significant difference from the control with p < 
0.01.  
 
Solution IC50 (µg/ml) 
Control  0.26 ± 0.03 
PD Fluid 0.45 ± 0.06* 
Sodium chloride 0.37 ± 0.03** 
Sodium lactate 0.32 ± 0.05 
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Figure 33. Sodium chloride and PD fluid, but not sodium lactate, interfere with the ability 
of SAP to inhibit fibrocyte differentiation. Cells were incubated in PD fluid or its components 
with and without various concentrations of SAP for 5 days. The number of fibrocytes were 
counted and normalized to the fibrocyte count without SAP. Values are mean ± SEM, n=3.  
 
 
Discussion 
Fibrocytes derived from monocytes are commonly found in fibrosing diseases 
such as congestive heart disease and renal fibrosis (232, 233). Long-term peritoneal 
dialysis often results in the formation of fibrotic tissue within the peritoneum (208, 210-
214). Here we show that fibrocyte differentiation is potentiated by PD fluid and two of 
its components, sodium chloride and sodium lactate. PD fluid and sodium chloride 
appear to block the ability of serum amyloid P (SAP) to inhibit fibrocyte differentiation. 
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Sodium lactate potentiates fibrocyte differentiation in a mechanism independent of SAP 
inhibition.  
 PD fluid, sodium chloride, and sodium lactate potentiated fibrocyte 
differentiation. Cells were confirmed to be fibrocytes due to the increase in collagen 
observed after PD fluid, sodium chloride, and sodium lactate incubation. An increase of 
any cell type could be due to an increase in cell proliferation. Previous work with 
fibrocytes did not identify any changes in fibrocyte or fibrocyte precursor proliferation 
(234). We analyzed the number of adherent, and therefore viable, cells to determine if 
there was an increase in proliferation after 5 days with PD fluid or its components. We 
did not observe any differences in proliferation with any of the solutions used. 
Therefore, the increase in fibrocyte number is not due to an increase in total cell number.  
Previously our lab observed that ~155 mM of sodium and ~130 mM of chloride 
potentiated fibrocyte differentiation (226). We saw that PD fluid corresponding to a 
[Na+] of 150.5 mM and a [Cl-] of 119 mM potentiated fibrocyte formation. With the 
addition of sodium chloride alone, a [Na+] of ~146 mM and a [Cl-] of ~120 mM were 
able to potentiate fibrocyte differentiation. Additionally, when sodium lactate was added, 
a sodium concentration of 141 mM was able to potentiate fibrocyte differentiation. 
Potentiation of fibrocyte differentiation by sodium lactate was probably due to increases 
in sodium as the lactate concentration for potentiation was only 5 mM and PD fluid 
contains 40 mM lactate. These are comparable to our previous findings (226).  
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Peritoneal dialysis fluid pumped into the peritoneum contains 132 mM sodium 
chloride. The transport of ions across the peritoneal membrane has been shown to be 
dependent on the glucose concentration in the peritoneal dialysis fluid (235). Typical 
dwell times (time allowed for exchange to occur across the membrane) are 4-10 hours. 
With 1.5% glucose and a 4-hour dwell time, approximately 13.2 mM of additional 
sodium would be reabsorbed from the blood. This corresponds to approximately 145 
mM total sodium in the peritoneum. Assuming the same parameters, an additional 14 
mM of chloride would be reabsorbed, resulting in 111 mM chloride in the peritoneum 
retention fluid. 145 mM sodium and 111 mM chloride could cause potentiation of 
fibrocyte differentiation which would likely occur in the peritoneum over long-term 
treatment. 
 Serum amyloid P (SAP) inhibits the differentiation of fibrocyte by interacting 
with FCγRI on monocytes (236). Both PD fluid and sodium chloride influence the 
ability of SAP to inhibit fibrocyte differentiation. For unknown reasons, sodium lactate 
did not significantly influence SAP activity. This could be due to the necessity of 
chloride or a secondary effect of having lactate present. Alternatively, sodium lactate 
fibrocyte potentiation could be through a mechanism independent of SAP inhibition. 
Blocking SAP inhibition leads to an increased number of fibrocytes. Peritoneal fibrosis 
could be potentiated by inhibiting SAP in the peritoneum by whole PD fluid and 
specifically sodium chloride. Conversely, peritoneal fibrosis may be alleviated in 
patients undergoing long-term peritoneal dialysis by altering the sodium chloride levels 
in the PD fluid such that SAP is no longer inhibited.  
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APPENDIX E 
RBLA IS REQUIRED FOR APRA PROLIFERATION INHIBITION AND 
CHEMOREPULSION
1
 
 
Summary 
Retinoblastoma (RB) is a tumor suppressor that regulates cell proliferation. This 
is a target effector we would expect a signal that inhibits cell proliferation to activate. 
Work on the Dictyostelium knockout of RB , rblA¯, was completed by several members 
of our lab. The following dissertation appendix gives a summary of our findings, a short 
introduction about RB, and the results from the portion of the manuscript I completed 
myself.  
We found that the loss of RblA results in a higher maximum density of cells in 
shaking culture, due to increase cytokinesis and a low accumulation of the chalone 
CfaD. Cell lacking RblA are insensitive to AprA, but not CfaD. rblA¯ cells proliferate 
slower on bacterial lawns. RblA does not affect cell growth. In addition to its role in 
proliferation inhibition, RblA is necessary for the chemorepulsion by AprA.  
 
 
 
________________ 
1Reprinted with presmission Originally published in Eukaryotic Cell. Bakthavatsalam, D., M. J. White, S. 
E. Herlihy, J. E. Phillips, and R. H. Gomer. 2014. A retinoblastoma orthologue is required for the sensing 
of a chalone in Dictyostelium discoideum. Eukaryotic Cell 13: 376-382, Copyright 2014 by ASM. 
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Introduction 
RB is a tumor suppressor gene that regulates cell proliferation through 
controlling the entry of cells into S phase (237). RB typically binds to and blocks the 
transcription factors that are needed for S phase to begin (237). When the cell cycle is 
promoted, cyclin-dependent kinases phosphorylate RB to inhibit its binding (238). Cells 
then transcribe the necessary components to enter S phase (238). The loss of RB leads to 
the formation of retinoblastomas (239).  
In Dictyostelium, the retinoblastoma gene, RblA, also seems to regulate S phase 
mediators (240). Previous work has shown that cells lacking RblA had normal 
proliferation, but overexpression of RblA caused slower proliferation (240). We 
therefore, examined the role of RblA in the chalone signaling pathways for AprA and 
CfaD.  
 
Methods 
Proliferation on bacterial lawns was done as previous described (132) and colony 
size determination was done following Phillips (46).  
 
Results 
 To determine if like aprA¯  and cfaD¯ colonies, rblA¯ colonies expanded more 
slowly than wild type colonies, cells were plated and the average colony diameters were 
measured daily (46). rblA¯ colonies were significantly smaller than wild type colonies 
(Figure 34A). Interestingly, the colonies appeared to increase at the same rate, with 
 168 
 
rblA¯ cells having a delay in colony formation (Figure 34A). One explanation for slow 
colony expansion would be slow proliferation. We examined the proliferation of rblA¯ 
on bacterial lawns. At 24 hours after plating, wild type and rblA¯ cell density was 
similar (Figure 34B). However, at 48 and 72 hours after plating, there were significantly 
less cells than wild type. Together, this indicates that RblA aids is proliferation and 
colony expansion on bacterial lawns and the loss of this protein disrupts the ability of 
cells to proliferate and expand on bacteria.  
 
 
 
 
Figure 34: RblA facilitates bacterial proliferation and colony expansion. (A) Dilutions of 
log-phase cells were mixed with bacteria and spread on SM/5 plates. Well-spaced colonies were 
imaged daily and the average colony diameter was measured. Before day 3 for wild-type cells, 
and day 4 for rblA¯ cells, no clearing of the bacterial lawn was observed. (B) 103 cells were 
plated on bacterial lawns and the number of Dictyostelium cells was counted daily. For A and B, 
values are mean ± SEM, n = 7, the absence of error bars indicates that the error was smaller than 
the plot symbol, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 (t-test). 
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Discussion 
 We found that rblA- cell proliferation is significantly slower on bacterial lawns. 
To date, no other mutants (aprA¯, cfaD¯, cnrN¯, qkgA¯, or bzpN¯) we have screened 
within the chalone pathways have this phenotype (39, 40, 45, 46, 132). RblA regulates 
cell-cycle genes (237). There are three types of cytokinesis in Dictyostelium cells, at 
least one of which is dependent on substrate attachment . Therefore, it is possible that the 
loss of RblA disrupts a gene or protein necessary for substrate cell division and thus 
causes the slow proliferation and colony expansion on bacterial plates. It is also possible 
that RblA mutants have a defect in the ability to ingest or digest bacteria and therefore 
fail to clear plates as rapidly as wild type cells.  
 The inactive state of RblA would be un phosphorylated. RblA either lies within 
the AprA pathway itself or is acted up on by a component of the AprA pathway. AprA 
could active a kinase to phosphorylate RblA and therefore inhibit the transcription of 
factors leading to cell cycle progression. Future work will determine whether AprA acts 
directly or indirectly on RblA.  
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APPENDIX F 
A MECHANISTIC VIEW OF DPPIV CHEMOREPULSION 
 
Summary 
The work in this section of the dissertation is a compilation of elucidating the 
mechanism of DPPIV and examining the ability of DPPIV to act as a therapeutic for 
ARDS.  
Here we find that DPPIV can bind human neutrophils and that binding is affected 
by the addition of a DPPIV-enzymatic inhibitor. Gradients of DPPIV increase the 
number of cells with actin localized away from the source of DPPIV. Various 
concentrations of rDPPIV effectively reduce neutrophil accumulation in the lungs of 
mice. Additionally, nebulized rDPPIV chemorepulses human neutrophils and reduces 
neutrophils in mouse lungs. Together, gives insight into the mechanism used by DPPIV 
to induce chemorepulsion.  
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Introduction 
ARDS has a mortality rate of ~40% (101). It is characterized by neutrophil 
damage to the tissue and a loss of lung integrity due to edema and epithelial cell damage 
(106). Neutrophils release proteases and reactive oxygen species that damage the tissue 
(105, 106). One mechanism to resolve neutrophil damage would be to chemorepulse 
neutrophils from the lung tissue.  
DPPIV is an enzyme found on epithelial cells and some immune cells and as a 
soluble form in many bodily fluids (75, 82). We previously found that DPPIV acts as a 
chemorepellent of human neutrophils (187). DPPIV functions in a range above, below, 
and within the physiological concentration (400-800 ng/ml) of DPPIV. The enzymatic 
activity of DPPIV is necessary for neutrophil chemorepulsion. DPPIV does not cleave 
components of the media or neutrophil products that then act as chemorepellents. 
Oropharyngeal aspiration of DPPIV in a mouse model of ARDS reduces the 
accumulation of neutrophils in the lungs. Less neutrophils are present in the alveolar 
space and the lung epithelial tissue with DPPIV treatment. DPPIV does not inhibit or 
promote apoptosis in vitro and the reduction of neutrophils in the lungs of mice is not 
due to increased apoptosis. DPPIV acts as a chemorepellent and has the potential for a 
therapeutic of ARDS. 
Here we show that DPPIV can bind to neutrophils and like the chemorepulsion, 
is mediated by enzymatic activity. Gradients of DPPIV increase the number of 
neutrophils with actin polarized away from the source of DPPIV.  
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Methods 
Dilutions of Alexa647 labeled DPPIV were incubated with human neutrophils 
for 10 minutes, cells were collected, excess DPPIV removed, and fluorescence was 
measured by flow cytometry. Binding assays using DPPIV enzyme inhibitor (DPPIV 
1cHCl) were done similarly, except DPPIV was pre-incubated with the inhibitor before 
added to the cells. For actin localization, 8-well glass slides were coated with 20 µg/ml 
human fibronectin at 37°C for 30 minutes and wash twice with PBS. Human neutrophils 
at 3 x 106 cells/ml were plated in 200 µl volumes into each well. Cells were allowed to 
adhere to plates for 15-20 minutes, non-adherent cells were washed off, and remaining 
cells were left to settle for another 15 minutes at 37°C. A gradient of DPPIV was created 
by placing a drop of rDPPIV in one corner of the well. After 40 minutes, cells were fixed 
with 4% paraformaldehyde for 10 minutes, washed with PBS, incubated with 0.1% 
Triton X-100 for 2 minutes, washed and blocked with 1% BSA/PBS for 10 minutes. 
Cells were stained with Alexa-488 conjugated phalloidin for 20 minutes and mounted 
with DAPI. Cells were imaged with a 100x objective. Actin localization toward or away 
from the source of DPPIV was analyzed for one hundred or more cells using a 60x 
objective.  
 
Results 
rDPPIV binds neutrophils  
One way DPPIV could cause chemorepulsion is through binding to neutrophils. 
To determine if DPPIV could bind neutrophils, cells were incubated with labeled DPPIV 
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(DPPIV-Alexa) and fluorescence measured by flow cytometry. We found that DPPIV 
bound neutrophils (Figure 35). Intriguingly, there were two populations of binders. 
Some donors more strongly bound DPPIV (Figure 35C) than others (Figure 35B). This 
indicates that DPPIV can bind neutrophils.  
 
 
 
Figure 35: DPPIV binds human neutrophils. Neutrophils were incubated with various 
concentrations of DPPIV-Alexa and examined for the ability to bind DPPIV by flow cytometry. 
(A) Two populations of donors. (B) and (C) each population individually. Values are mean ± 
SEM (n≥5). 
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DPPIV binding is effected by DPPIV enzymatic inhibitors 
We previously saw that the chemorepulsion of neutrophils by DPPIV was 
dependent on its enzymatic activity (187). Binding assays were repeated with a DPPIV 
enzymatic inhibitor to determine if enzymatic activity was necessary for binding of 
DPPIV. The binding of DPPIV to neutrophils was affected by the addition of a DPPIV 
enzymatic inhibitor (Figure 36). This is supported by a significantly lower Bmax and 
increase in KD in the presence of the inhibitor. This indicates binding of neutrophils to 
DPPIV is dependent on the enzyme activity of DPPIV. 
 
 
Figure 36: DPPIV enzyme activity is necessary for binding neutrophils. Binding assays were 
repeated with an inhibitor of DPPIV enzyme activity. Curves are fit to one-site with Hill-
coefficient. Values are mean ± SEM, n ≥ 5.  
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DPPIV effects the localization of actin 
Chemoattractants signal to reorganize actin filaments (61). Actin filaments in 
actively chemotaxing cells are localized to the leading edge (61). In the case of a 
chemoattractant, this would be the edge closest to the attractant. One would expect if 
chemorepellents use similar mechanisms, the actin would localize at the leading edge, in 
this case the edge facing away from the repellent source. Neutrophils in a gradient of 
DPPIV were fixed and stained with phalloidin-Alexa488 to observe actin localization. 
Localization was visualized and polarized cells were imaged and counted. The percent of 
cells moving up and down the gradient were counted. Here, ‘toward’ indicates actin is 
polarized closest to the source of DPPIV and ‘away’ indicates actin was polarized at the 
cell edge farthest from the source of DPPIV. In both the control and gradient wells, 
approximately 11% of cells had actin polarization in the toward direction (Figure 37). In 
the control well, 6% of cells had actin polarized away. This increased to ~26% in DPPIV 
gradient wells. This suggests that DPPIV may use actin dynamics to regulate 
chemorepulsion.  
 
 
 
 
 
 
 
 176 
 
 
Figure 37: DPPIV affects actin polarization. Human neutrophils were fixed and labeled with 
phalloidin-Alexa488. (A) A representative image from control well and (B) a representative 
image of a cell moving away from DPPIV in the gradient well are shown. (C) Quantification of 
phalloidin localization. Percentage of cell polarized toward or away from DPPIV out of total 
cells in shown. Values are mean ± SEM (n=3). p  < 0.05 (t-test). 
 
 
 
Discussion 
The work in this section of the dissertation examines the mechanism through 
which DPPIV acts as a chemorepellent. We found that DPPIV can bind to human 
neutrophils and that this binding is affected by the addition of enzyme inhibitors of 
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DPPIV enzymatic activity. Gradients of DPPIV increase the number of cells that have 
actin polarized away from the source of the DPPIV.  
DPPIV enzyme activity is required for the chemorepulsion of human neutrophils 
(187). There was heterogeneity in the binding properties of DPPIV. We found that 
enzymatic activity is also necessary for neutrophil binding of DPPIV. It is unclear 
whether DPPIV is actually cleaving a membrane component of neutrophils or the 
substrate pocket is just necessary for neutrophil binding. DPPIV contains a caveolin 
binding domain in the substrate pocket including Ser630, part of the enzymatic triad 
(241). This evidence suggests that DPPIV could be using the substrate pocket without 
cleaving. Blocking the site with inhibitors, could prevent binding of DPPIV to 
neutrophils.  
  Chemoattractants cause polarization of cell components. Cells in a gradient of 
chemoattractant have PTEN localized to the rear of the cell (the part farthest away from 
the chemoattractant) to prevent pseudopod formation in the wrong direction (38, 51, 58-
60). At the leading edge (the edge closest to the chemoattractant), PIP3 and Rac are 
enriched, leading to actin polymerization and pseudopod formation (61). Evidence 
suggests that chemorepellents function in a reverse of this mechanism where PTEN 
would be localized closest to the repellent to prevent movement toward it (38, 51, 58-
60). Here we found that the chemorepellent DPPIV uses actin dynamics for cells 
movement. A general increase in actin polarization at the membrane is seen in gradients 
of DPPIV. Additionally, gradients of DPPIV increase the number of cells with actin 
localized farthest from the source of DPPIV. Based on the actin localization, these cells 
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would be moving away from the DPPIV. This suggests that DPPIV chemorepulsion 
affects actin dynamics.  
 
Conclusions and future directions 
Work done in this section of the dissertation analyzes the mechanism of DPPIV-
induced chemorepulsion. DPPIV can bind neutrophils in an enzyme-dependent manner. 
Future work on DPPIV binding will focus on identifying the receptor or binding partner 
of DPPIV. It will also determine whether DPPIV cleaves the partner or if the substrate 
pocket is necessary for binding. Future work on the mechanism will examine other 
known components of chemotaxis pathways such as PTEN for their localization in 
response to DPPIV gradients.   
 
